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 Cigarette smoking is the leading cause of preventable death in the United 
States.  While there are more than 4,000 chemicals found in tobacco smoke, the 
polycyclic aromatic hydrocarbons (PAHs) have been clearly demonstrated to 
contribute to smoking-related cancers.  Of this group of compounds, benzo(a)pyrene 
(B(a)P) is concidered to be the most carcinogenic and its ability to cause lung 
tumors is well documented.   
Many conventional biomarker assays conducted today use the 
measurement of nicotine (and its metabolite cotinine) in blood, urine, or oral 
fluids for assessment of tobacco smoke exposure. However, these conventional 
assays do not measure exposure to carcinogenic compounds and are sensitive 
only to recent smoke exposures. Due to the ease of hair sampling and its 
extended detection window of substances incorporated into its matrix, this 
dissertational research proposes a promising new tool for the assessment of 
toxic tobacco smoke exposure. 
We investigated the disposition of B(a)P and its electrophilic reactive 
metabolite, trans-7,8-dihydroxy-anti-9,10-epoxy-7,8,9,10-tetrahydro-
benzo(a)pyrene (BPDE), in rat and human hair.  BPDE is one of the most potent 





multiple tissues. Our overarching hypothesis was that B(a)P and BPDE-protein 
adducts in hair can be used as biomarkers of toxic B(a)P exposure. 
The data presented in this dissertation demonstrate that B(a)P and BPDE-
protein adducts are incorporated into rat hair in a dose-dependent manner.  
While B(a)P incorporation into rat hair is not dependent upon pigment content, 
BPDE-protein adducts concentrations are significantly greater in pigmented vs. 
nonpigmented hair.   
 Gross histopathological changes in rat lung tissue, such as alveolar wall 
thickening, decreased air space, and macrophage hyperplasia were visually 
evident in rats 14 days after B(a)P administration. Immunohistochemistry staining 
for myeloperoxide content (a marker for neutrophils) in the lung tissue of B(a)P-
dosed rats was also significantly greater than vehicle control rats. 
B(a)P can be detected in human hair, but BPDE-protein adducts could not 
be detected, despite evidence of active smoking status via plasma cotinine 
concentrations.  
The results of this dissertational research demonstrate that hair may serve 
as an easily accessible surrogate tissue for the detection of a biomarker of toxic 
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 This chapter provides an introduction to the anatomy and physiology of 
hair, the history and science of hair testing, the role of biomarkers in toxicology, 
and a brief background on benzo(a)pyrene (B(a)P). This overview concludes with 
the objectives of this dissertational research and the experiments designed to 
test the overarching hypothesis. 
 
Anatomy and Physiology of Hair 
 
While hair may appear to be a simple structure, it is actually very complex, 
and to this day is only partially understood.  A great deal still remains to be 
learned about hair growth and its anatomy.  
Mammalian hair consists of proteins (65-95%), lipids (1-9%), pigment (0.1-
5%), minerals (0.25-0.95%), and small quantities of water [2-9] and grows from 
follicles found in the epidermal epithelium. Hair has two distinct structures: 1) the 
hair follicle (portion below the skin) and; 2) the hair shaft (portion above the 
skin).  
The only biologically active portion of hair is the hair follicle itself.  The 





3-4 mm below the skin’s surface.  The follicle also contains oil-producing 
sebaceous glands (which lubricate the hair) and arrector pili muscles (which can 
erect the hair) (see Figure 1.1).  The follicle is the only organ in mammals that 
undergoes life-long cycles of rapid growth (anagen), regression and transition 
(catagen), and resting periods (telogen)(see Figure 1.2). The exact molecular 
mechanisms that drive this oscillating system remain unclear. However, it is 
recognized that the transformations in hair follicle cycling are controlled by the 
expression and activity of hormones, neurotransmitters, transcription factors, 
cytokines, enzymes, and cognate receptors [10]. These factors can also 
contribute to the typical growth rate of hair seen in mammals.  For scalp hair in 
humans, the average growth rate is generally assumed to be 1 cm/month (or 
0.45 mm/day for women / 0.44 mm/day for men) [11].  However, a wide range of 
growth rates from 0.6 cm/month (0.2 mm/day) to 3.36 cm/month (1.12 mm/day) 
have been reported [11-13].  Growth rates can also change with age, pregnancy, 
and nutritional status [9, 14].  Additionally, these rates are dependent upon 
anatomical location, gender, and race. In the rat, the average growth rate is 
faster (about 1 mm/day), however, the anagen phase is much shorter (about 16-
20 days) [15] compared to that of humans (2- 6 yrs)[1].  
 In contrast to the hair follicle, mature hair shafts are nonliving biological 
fibers, whose cells are void of nuclei. The cells that make up the hair shaft 
become cornified during the process of epithelial differentiation. This cornification  
occurs when keratin protein is incorporated into longer keratin-intermediate 










Figure 1.1  Follicle anatomy. A) Histologic longitudinal section of follicle on the 
left hand side; Schematic drawing of follicle with anatomical details on the right   
hand side. B, Hair bulb in detail (enlargement of schematic drawing in A). 
 
APM, arrector pili muscle; CTS, connective tissue sheath; DP, dermal papilla; 
IRS, inner root sheath; ORS, outer root sheath; SG, sebaceous gland (modified 
after [16]) 
 












































Figure 1.2 Hair cycle phases.  A) The hair cycle clock showing average length of 
each phase. B) Representative drawings showing each phase of the hair cycle 
[10].  
APM, arrector pili muscle; CTS, connective tissue sheath; DP, dermal papilla; 
IRS, inner root sheath; ORS, outer root sheath; SG, sebaceous gland (modified 
after [16]) 
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cell nucleus disappears.  Cell metabolism also ceases, and the cell undergoes 
apoptosis once completely keratinized. This feature of hair (i.e. non-living tissue) 
contributes to the stability of xenobiotics in hair; if metabolic activity ceases, then 
xenobiotics are not being metabolized or broken down and excreted. 
The hair shaft can be divided into three zones (see Figure 1.3): 1) The 
cuticle, or outer layer, consists of six to ten organized layers of thin flat cells that 
overlap like shingles; 2) The cortex, which contains keratin rod-like bundles and 
constitutes the bulk of the hair shaft. The cortex also contains melanin granules, 
which depending on the type, number, and distribution determines the hair 
shaft’s color; 3) And last, the medulla, an open unstructured region in the fiber’s 
center (gray hair can be void of a medulla where beard hair can possess a 
double medulla) [2, 17].  This region constitutes only a small percent of the 
overall mass of the hair fiber.  
 The predominant protein that makes up the hair shaft is keratin.  This 
protein assembles into monomers, then subsequently into bundles to form rope-
like intermediate filaments which provide strength and durability to the hair fiber.  
The biochemical feature that contributes to this physical strength of the fiber is 
disulfide bonding between keratin and other high sulfur proteins [18].  Some of 
the major amino acids that make up the keratin protein are glycine, threonine, 
aspartic acid, glutamic acid, lysine and very importantly cysteine [1].  Human hair 
is made up of approximately 14% cysteine, which contributes to the high sulfur 
content in hair [19].  The sulfhydryl group on cysteine is a potential binding site 









Figure 1.3 Cross-sectional drawing of hair showing cuticle, cortex and medulla 
zone in hair.  (Modified from Gray’s Anatomy [22].) 
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hair include the hydrocarbon side chains in glycine, the hydroxyl side chains in 
threonine, and the primary amide in aspartic and glutamic acid [23]. 
 
Hair Color and Its Importance in Drug Disposition  
Certain drugs have been demonstrated to bind to darker hair to a greater 
extent than lighter colored hair [24-36].  Hubbard et al. demonstrated that 
cocaine, a basic drug, was incorporated into pigmented rat hair two orders of 
magnitude greater than nonpigmented rat hair [37]. This observation can be 
explained, in part, by the greater quantity of melanin present in pigmented hair 
compared to nonpigmented hair.  
Melanin is a polyanionic polymer that can be found in hair, skin, the 
substantia nigra of the brain, the inner ear, and the uveal tract of the eye.  In hair, 
melanin is produced by melanocytes and transferred to melanosomes in 
differentiating cortical and medullar cells.  During the growth of a hair strand, 
these melanin-containing cells move upward from the hair follicle to the hair shaft 
and reside in the cortex and medulla layers (see Figure 1.1 B) [17].  The outer 
cuticle cell layer contains little to no melanin [38].  In addition, the quantity of 
melanin in hair can vary over one’s lifespan, and from follicle to follicle.   
Melanin is a derivative of the amino acid tyrosine (see Figure 1.4 A) and 
has multiple negatively charged carboxyl groups and o-semiquinones [39-41] 
binding sites for cationic xenobiotics (e.g., metals and compounds containing 
amine groups) [42] that are positively charged at physiological pH [41, 43]. B(a)P, 
an uncharged, lipophilic molecule, has also been demonstrated to bind melanin  
























Figure 1.4.  Chemical structures of L-tyrosine, eumelanin, and pheomelanin. A)   
L-Tyrosine structure, B)  Proposed chemical structure of eumelanin* C)  
Proposed chemical structure of pheomelanin* (-COOH can also be H or other 
substituents (rare).  Lines indicate where the polymer continues. (*with 









In general, the more melanin that is present in the hair shaft, the darker 
the hair color (e.g., brown and black hair).  If less melanin is present, the hair 
color will be lighter (e.g blond hair).  The specific color of the hair shaft results 
from two types of hair melanin: 1) eumelanin, the dominant pigment in brown and 
black hair (see Figure 1.4 B); 2) and pheomelanin, the dominant pigment in red 
hair (see Figure1. 4 C). Gray hair color results when melanin concentrations are 
extremely low to nonexistent.   
 
The History and Science of Hair Testing 
 Hair analysis was used in the 1960s and 1970s to evaluate exposure to 
toxic heavy metals by atomic absorption spectroscopy.  Starting in the early 
1980s, researchers in the U.S. and Germany determined the presence of various 
organic drugs in hair by means of radioimmunoassay (RIA). Gas chromatography 
coupled with mass spectrometry (GC/MS) is the current method of choice for hair 
analyses due to high selectivity, sensitivity and specificity.  However, other 
methods such as liquid chromatography coupled to tandem mass spectrometry 
(LC/MS-MS) are increasingly being used for hair testing. 
 Hair testing has been applied to a wide range of chemicals, and used in 
multiple settings from occupational to environmental to alternative medicine.   
Although controversial, hair mineral analyses have been used to diagnose and  
treat mineral deficiencies for over 20 years in alternative medicine practices.  
Although researchers have generally used hair testing as a way to monitor 






[49-51]), much of the focus has been directed towards the detection and 
quantification of drugs of abuse, particularly in forensic and clinical toxicology. 
There are many advantages in testing for analytes in hair compared to 
plasma, urine, or oral fluids.  First, there is a longer detection window with hair 
testing compared to the testing of blood, oral fluid, or urine [52].  In general, the 
detection window for urine and blood analyses is up to 3 days, while hair testing 
can be from weeks to months, or even years with certain chemicals [52].  
Furthermore, when segmental hair analysis is employed, it may be possible to 
provide a xenobiotic exposure history [53-55].  Second, analyses of biomarkers 
in hair can more accurately account for chronic exposure [1, 56, 57].  Third, 
concentrations of biomarkers measured in hair are cumulative, therefore are less 
affected by daily fluctuations in intake/exposure;  Specifically, in the case of 
tobacco use, concentrations of nicotine and cotinine measured can adjust for 
different tobacco products used over time and the different manners in which 
humans smoke cigarettes [1, 56, 57]. Fourth, hair samples are less susceptible to 
tampering than urine, and do not decompose like other body fluids or tissues. 
Fifth, using hair has the advantage of being easily collected with minimal 
discomfort, and does not require the specialized personnel that blood draws 
necessitate. Last, with regard to smoking, hair testing has been demonstrated to 
better correlate with self-reported tobacco exposures, compared to conventional 
testing [1, 56].  
While hair testing does provide some major advantages, it is not without  





incorporation and stability of drugs/xenobiotics in hair, as well as general  
influences on hair growth (i.e. nutritional status, pharmaceuticals, ethnicity, 
gender, hormones, etc.).  There are still many important questions that remain 
concerning the mechanisms of drug/xenobiotic incorporation into hair, as well as 
the effects of external contamination and the stability of the xenobiotics in hair 
through daily hygiene and cosmetic procedures. Confounding these issues are 
possible individual factors, which still remain largely unidentified.  
 
Role of Biomarkers  
 Currently, intensive work is taking place on the discovery and 
development of innovative biomarkers of cancer risk. Optimally, these 
biomarkers would serve to determine if there is an increased risk of cancer for an 
individual, and therefore specific countermeasures could be put in place and the 
individual could be closely monitored. 
In the case of tobacco-related biomarkers, the main focus has been on 
nicotine specific metabolites. Yuan et al. (2009), conducted a nested case 
controlled study involving 246 cases of lung cancer in which they determined 
urinary levels of cotinine and  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL) a metabolite of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone  (NNK), a 
nicotine specific carcinogen. Their study suggested that urinary levels of cotinine 
and NNAL can be used as biomarkers of increased lung cancer risk [58]. 
To our knowledge, research to assess increased cancer risk via hair 
analysis of any tobacco-related chemical has not been performed. Several 





conventional methods have been previously discussed, but whether testing hair 
for chemicals found in tobacco smoke can be used as a biomarker of cancer risk 
remains to be elucidated.  The detection of the carcinogen B(a)P in human hair 
has only been reported in one small study involving 20 subjects [59].  None of 
B(a)P’s metabolites, including benzo(a)pyrene diol epoxide (BPDE) or BPDE-
protein adducts, have been reported in human hair to our knowledge. BPDE 
adducts to hemoglobin and albumin, as well as BPDE-DNA adducts, have been 
studied extensively [60], but the collection of these samples is invasive, and often 
are not detected (>60% for DNA adducts and about 40% for protein adducts) 
[60]. It is important to identify individuals with higher cancer susceptibility, and 
determining individuals who metabolically activate B(a)P to BPDE more 
extensively, and/or detoxify BPDE less, are presumed to have a higher cancer 
risk. Therefore, the BPDE-protein adduct biomarker in hair could help to facilitate 
many ongoing studies regarding activity-affecting polymorphisms in high-risk 
individuals with variations in B(a)P metabolizing enzymes such specific 
cytochrome P450s isoforms, epoxide hydrolase, as well as B(a)P detoxifying 
enzymes such as glutathione S-transferase. These biomarkers could also be 
applied in the testing of chemoprevention agents in B(a)P exposed animals.  
Lastly, this research can facilitate and address exposure and risk reduction not 
only for tobacco smoke exposure in multiple settings, but also for occupational 









hydrocarbons (PAHs) (formerly called polynuclear aromatic hydrocarbons) 
and is found in virtually all PAH mixtures.  These compounds are formed by the 
incomplete combustion of organic matter and are commonly found in tobacco 
smoke, polluted air, water, and broiled/smoked foods [61-66].  B(a)P is also 
found in diesel exhaust  and certain occupational settings, such as coking plants 
and graphite electrode producing plants [67-69]. Many of the PAHs are 
carcinogens, but B(a)P is considered the most potent. 
B(a)P can enter the body through the lung, gastrointestinal tract, and skin. 
Conclusive evidence has demonstrated that B(a)P can readily induce tumors in 
laboratory animals in various tissues at relatively low doses [62, 70-73]. 
Independent of the route of exposure, one of the target tissues for B(a)P is 
considered to be the lung, and accumulation of B(a)P in the lungs of rats has 
been demonstrated [74, 75].  While, B(a)P is classified as a human carcinogen 
by the International Agency for Research on Cancer [73], animal studies have 
also suggested adverse developmental and reproductive outcomes with long-
term B(a)P exposure [76]. Moreover, B(a)P is known to be an endocrine disruptor 
and is arthrogenic, in addition to being genotoxic and carcinogenic [77-81].  
The U.S. Environmental Protection Agency (EPA) estimates the exposure 
to B(a)P is 1-3 ug/day for nonsmokers [76].  The amount of B(a)P exposure can 
vary widely in smokers (due to the different products on the market, and 
individual variations in smoking behavior), but are estimated at 1-30 ug/pack/day 
[63, 82-85].  B(a)P itself is considered a procarcinogen, and requires metabolism 





multiple metabolites of varying toxicity.  The metabolism to the ultimate 
carcinogen BPDE is depicted in Figure 1.5.  BPDE has been thoroughly 
demonstrated to be the most mutagenic and carcinogenic of the B(a)P 
metabolites [86-90].  BPDE is electrophilic, and binds covalently to nucleophilic 
groups on DNA (predominately the amino group of deoxyguanosine by the trans 
addition to carbon 10 of BPDE) and vital proteins in a highly stereospecific 
manner [91-95]. The Bay Region (see Figure 1.5) of the B(a)P molecule forms an 
angular ring area of steric hinderance and impedes detoxification of BPDE by 
glutathione conjugation, glucuronidation, and sulfation [70, 78, 88, 96], which 
contributes to its toxicity.  
Rodent and human subcellular fractions have thoroughly demonstrated 
that the trans, anti- enantiomer of BPDE (B(a)P-r-7,t-8-dihydrodiol-t-9,10 
epoxide) is the major product of epoxidation of trans B(a)P 7,8 diol (B(a)P r-7,r-8-
diol) [70, 87, 97] (see Figure 1.5), although other minor enantiomers are also 
formed.  The majority of BDPE-induced adducts are produced by the reaction 
with this enantiomer [70, 94].  Analysis of BPDE-induced adducts from B(a)P-
treated animals and from humans exposed to B(a)P reveal that B(a)P-r-7,t-8,t- 
9,c-10-tetrahydrotetrol (BPT) is the predominant compound released upon 
hydrolysis of these adducts [70, 97, 98]. Like most research on BPDE-induced 
adducts, our research focuses on the detection of this major product from the 
hydrolysis of trans, anti-BPDE-induced adducts.  The measurement of BPT 
therefore serves as evidence of a BPDE-induced adduct.  Recently, Ragin et al.  


































Figure 1.5.  Metabolic activation scheme of the activation of the B(a)P to the 
reactive electrophilic intermediate trans, anti-BPDE. This reaction is completed 
by specific CYP450s (predominately CYP1A1 and  CYP1A2 and CYP1B1 to a 
lesser extent) and epoxide hydrolase to eventually form the BPDE-protein adduct 
[88, 96, 99, 100].  During preparation of samples, the BPDE-protein adduct is 












tetrahydrotetrol released from BPDE-Hb adducts in a small group of human 
participants [93].  Enzyme-linked immunosorbent assays (ELISA) have been 
used for whole protein adduct detection [101, 102], but require custom BPDE-
specific antibodies. These antibodies are expensive, may not always be 
available, and the potential exists for non-specific binding to other PAH adducts. 
 
Research Objectives 
The objective of this research was to investigate whether B(a)P and/or 
BPDE-protein adducts measured in hair can be used as novel biomarkers of 
toxic exposure to B(a)P.  The overarching hypothesis for this research was that 
B(a)P and BPDE-protein adducts in hair can be used as biomarkers of toxic 
exposures to B(a)P. To address this hypothesis the following specific aims were 
proposed: 
1. Develop sensitive and specific mass spectrometry methods to detect and 
quantify low concentrations of B(a)P and BPDE-protein adducts in biological 
matrices. 
2. Determine the concentrations of B(a)P and/or BPDE-protein adduct 
concentrations in hair and whether these concentrations are related to lung 
tissue damage in rats exposed to increasing amounts of B(a)P. 
 3. Determine the differences of B(a)P and BPDE-protein adducts in the hair of 
active smokers (those exposed to particulate tobacco smoke (PTS)) and  














QUANTIFICATION OF THE BIOMARKERS B(A)P AND BPDE- 





Mechanisms of xenobiotic incorporation in hair 
B(a)P and BPDE-protein adduct concentrations, in an easily accessible 
surrogate tissue like hair, may reflect concentrations in a target tissue such as 
the lung. There have been a number of studies that show a positive correlation 
between the amount of drug found in hair and the dose administered [103-107]. 
However, this is not always the case [108]. There are several proposed models 
for the mechanisms of drug/ xenobiotic incorporation into hair [1, 52, 108, 109]. 
There are also many factors that influence drug/xenobiotic incorporation in hair, 
such as the physiochemical properties of the drug/xenobiotic (melanin affinity, 
basicity, lipophilicity, pKa, etc.) and its bioavailability, volume of distribution, and 
plasma elimination half-life [28, 110-115]. With these factors in mind, the 
following is a brief discussion of xenobiotic incorporation into hair. 
 The passive diffusion model is the simplest model proposed, and 
involves the passive diffusion of chemicals (from the vascular system that 





base of the hair follicle. These chemical then ultimately become tightly bound in 
the interior of the hair shaft following keratogenesis. 
Since not all the data from studies of drug incorporation into hair fits the 
passive diffusion model, a second, more complex multicompartment model has 
been proposed.  This model unites the theory of chemical incorporation via the 
blood during keratogenesis with additional incorporation of chemicals from sweat 
and sebum secretions after the hair has formed (but before the hair has emerged 
from the skin’s surface). This model also accounts for the transfer of chemicals to 
the growing hair from the other compartments that surround the hair follicle, and 
the contribution of chemicals incorporating from the external environment after 
the hair has emerged from the skin (i.e., from smoke or vapors). 
A third model, the deep compartment model, has been proposed as a 
way to explain the unusual elimination of drugs such as cocaine and its 
metabolites from hair, as well as for very lipophilic compounds such as 
tetrahydocannbinol (THC) [108]. This model accounts for chemicals entering the 
hair via intradermal transfer from the accumulation of certain drugs into skin 
layers and other compartments such as erocrine (or eccrine) and apocrine 
glands. 
The last model, the melanin-binding model, includes the binding of 
xenobiotics to melanin.  In this model, differences observed in xenobiotic 
incorporation into hair would be dependent on the amount of melanin present in 
hair, and the inter-individual differences of the types of melanin that are present 





containing basic compounds, such as cocaine, nicotine, amphetamines, and 
morphine [28, 104, 112, 116, 117]. Several investigators have been able to 
demonstrate that these drugs are incorporated to the greatest extent in black hair 
compared to brown or blond hair [36, 118, 119]. Since melanin becomes 
incorporated into the hair shaft as the hair grows, the higher the melanin content 
(i.e. the darker the hair color), the higher the expected concentration of the 
drug/xenobiotic.  For example, black hair would represent the highest 
concentration of the drug/xenobiotic compared to lighter hair colors regardless of 
the same dose being given.  
Several different animal models have been used to study the incorporation 
of drugs/xenobiotics into hair, but the Long-Evans (LE) rat has a distinct 
advantage over the other models. This strain of rat has both pigmented and 
nonpigmented hair, thus eliminating the need to use two different strains to 
obtain both hair types.  This allows the investigator the ability to study the effects 
that pigmentation may have on the incorporation of xenobiotics into hair.  In 
addition, the use of only one strain of rat eliminates the need to consider the 
metabolic and pharmacokinetic differences of xenobiotic handling amongst 
different strains of rats. 
 The experiments presented in this chapter were designed to address the 
following objectives:  1) Develop sensitive and specific GC/MS methods 
(operated in electron ionization mode with selective ion monitoring, GC/MS-EI-
SIM) methods to detect B(a)P in hair, lung, and plasma.  2) Develop sensitive 





NCI-SIM) to detect BPT released from BPDE-protein adducts from hair and 
hemoglobin.  3) Using these developed methods, determine if B(a)P incorporates 
into rat hair in a dose-dependent manner.   4) Determine if B(a)P concentrations 
are greater in pigmented vs.nonpigmented rat hair. 5) Determine if BPT, released 
from BPDE-protein adducts, can be detected in rat hair, and whether 
concentrations are dose-dependent. 6) Determine whether concentrations of 
BPT released from BPDE-protein adducts in pigmented and nonpigmented hair 
statistically differ. 7) Determine if the concentration of B(a)P and/or BPT in hair 
correlate to formation of the BPDE-Hb adduct (the positive control).  8) 
Determine if B(a)P concentrations in hair reflect concentrations in a target tissue 
(lung) and plasma. 
 
Materials and Methods 
 
Chemicals and reagents 
 
 Benzo(a)pyrene (1 mg/mL) was purchased from SPEX Certiprep® Inc. 
(Metuchen, NJ), Restek (Austin, TX ), and AccuStandards®  (2 mg/mL)( New 
Haven, CT) for the preparation of calibration curves and quality control samples. 
The internal standard B(a)P-d12 (1 mg/mL), was purchased from SPEX 
Certiprep®, Inc.(Metuchen, NJ). For the dosing solutions, neat B(a)P (>96% 
purity) was purchased from Sigma-Aldrich® (St. Louis, MO). The vehicle for 
dosing solutions was corn oil (Mazola®, ACH Food Companies; Summit, IL).  
BPT (5 mg) was purchased from the National Cancer Institutes Chemical 





[13C6]-BPT (1 mg), was purchased from Cambridge Isotopes Laboratories, Inc. 
(Andover, MA) by Dr. Stephen Hecht of Masonic Cancer Center (University of 
Minnesota), and a generous gift of a 1200 ng/mL [13C6]-BPT solution (1mL in 
DMSO) was provided for this dissertational research.  Hexane, dichloromethane 
(DCM), methanol, acetonitrile, ethyl acetate were all GC/MS or high performance 
liquid chromatography grade and purchased from Burdick & Jackson
®
 
(Muskegon, MI).  Acetone (GC/MS grade) was purchased from EMD (Gibbstown, 
NJ), and anhydrous tetrahydrofuran (THF) was purchased from Sigma-Aldrich®     
(Milwaukee, WI). The derivatization agent (N-Methyl-N-(trimethylsilyl) trifluoro-
acetamide activated II, MSFTA II) was purchased from Fluka (Castle Hill, New 
South Wales, Australia).  Proteinase K (from Tritirachium album, activity >30 
units/mg) was purchased from Sigma-Aldrich®.  Sep-Pak C18, 3cc solid phase 
extraction (SPE) cartridges were purchased from Waters Corporation (Milford, 
Massachusetts). All other reagent grade chemicals were purchased from Fisher 
Scientific (Pitsburg, PA), Sigma-Aldrich® and Fluka.  Water used was either 
house-prepared Milli-Q water or NANOpureTM water obtained from ARUP 
Laboratories (Salt Lake City, Utah). Helium and ammonia gases used for GC/MS 
analysis were purchased from Airgas, Inc.® (Salt Lake City, UT). Whole blood 
from LE rats was obtained from Innovative Research (Novi, MI) for preparation of 
plasma and hemoglobin standards and quality control samples.  RBC lysis buffer 
was purchased from Roche (Branford, CT) and phosphate buffered saline 
solution from Teknova (Hollister, CA). Sodium heparin Vacutainers® 





 units/mL) and sterile saline were purchased from the University of Utah’s 
Outpatient Pharmacy (50 North Medical Drive, Room 1400, Salt Lake City, UT. 
84132). Procter and Gambler Company’s (Cincinnati, OH) Herbal Essences® 
shampoo was obtained from local retail store. 
 
Stocks and solutions 
 
Intermediate stock solutions of B(a)P were prepared in 1:1 (v/v) 
acetone/DCM at a concentration of 500 and 5000 ng/mL. Intermediate stock 
solutions for BPT were prepared in fresh anhydrous THF at a concentration of 
100 ng/mL.  Since B(a)P and BPT are light and air sensitive, all solutions were 
made in amber vials with septum screw caps to avoid over exposure to light and 
air and stored at -20°C.  Matrix fortified calibration curves and quality control 
samples were prepared daily. The quality control samples for B(a)P (that were 
prepared with each batch of samples and for determination of assay imprecision 
and accuracy) were fortified with a reference material from a different 
manufacturer than the reference material used for the calibration curve.  Since no 
other commercial source was available for BPT, a separate stock and 
intermediate solution for fortification of quality control samples were prepared by 




Male Long-Evans rats (200-225g) were individually housed in cages with  
wire mesh bottoms to eliminate the potential for external contamination of the 





temperature and lighting conditions (12 hr light/dark cycle) and provided with 
food and water ad libitum. All procedures were in compliance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals [120]. 
 
Multiple-dose hair experiments 
 
Prior to exposure, an approximate 2 inch medial dorsal square of 
pigmented and nonpigmented hair was shaved with an electric shaver (hair 
sample used for baseline measurements). The rats were then administered 
B(a)P (in corn oil) intraperitoneal (i.p.) at 40 mg/kg (n=10),  80 mg/kg (n=10), or 
160 mg/kg (n=10) once daily for seven days. (Solutions of B(a)P in corn oil were 
prepared at 25, 50, and 100 mg/mL for the 40, 80, and 160 mg/kg doses 
respectively. This was done in order to maintain a consistent volume of B(a)P in 
corn oil between the doses and groups). Control rats (n=10 total) were 
administered corn oil (i.p.), once per day for 7 days. Fourteen days after the first 
dose, the animals were anesthetized with chloral hydrate (450 mg/kg) and 
approximately a 1.5 inch medial dorsal square (inside the original 2 inch area) 
was shaved to collect newly grown pigmented and nonpigmented hair. These 
hair samples were then stored in air tight containers in the dark at 4°C (see 
dosing paradigm in Figure 2.1). While still under deep anesthesia, an abdominal 
aorta blood draw was performed with a sodium heparin-lined 10 mL syringe 
equipped with a 21 gauge needle. Blood was then transferred to a sodium  
heparin BD Vacutainer
® tube.  The animal’s diaphragm on each side was then 






7 daily i.p. doses of B(a)P (40 mg/kg,     
80 mg/kg, or 160 mg/kg)
Hair collected 
(Baseline)
Last day of 
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Figure 2.1. Dosing paradigm for Long-Evans rats. A)  Picture of Long-Evans rat 
showing area of shaved hair.  B) Dosing paradigm for B(a)P and time points of 
hair collection.  Prior to exposure, a medial dorsal ~2 inch square of pigmented 
and nonpigmented hair was shaved (hair sample used for baseline 
measurements). Rats were then administered B(a)P (in corn oil) i.p. at 40 mg/kg 
(n=10),  80 mg/kg (n=10), or 160 mg/kg (n=10) daily  for seven days. Control rats 
(n=10) were dosed i.p. with corn oil for seven days. Fourteen days after the first 
dose, a ~1.5 inch medial dorsal (inside the original 2 inch square) area was 
shaved to collect newly grown hair. Hair samples were then stored in air tight 
containers in the dark at 4°C until analysis.  This dosing paradigm was based on 
literature searches for commonly used B(a)P dosing protocols, to ensure BPDE-
Hb adduct formation would be adequate for detection, and to allow for the growth 







extracted by the trachea avoiding actual contact with the lung at all times. The 
left lobe was placed in 10% formalin (for histology). The right lobe was placed on 




B(a)P:  Hair preparation and extraction 
Ten milligrams of hair (+10%) were weighed (Mettler Toledo, AG104) and 
B(a)P-d12 internal standard (IS) added. Calibrators were concurrently prepared 
by fortification of B(a)P and IS to analyte-free (blank) rat hair.  After digestion of 
the hair (sonication in 1.5 mL of 2.5 N sodium hydroxide for 2 hrs) a liquid-liquid 
extraction was performed.   Hexane (1.5 mL) was added to each hair sample 
digest, thoroughly vortexed, and then centrifuged at 3500 rpm for 4 mins to 
minimize the emulsification layer. This was performed a total of three times, then 
combined organic fractions were dried under a constant stream of nitrogen in a 
Zymark Turbovap® LV evaporator at 55°C. Residues were then reconstituted in 
0.100 mL of 1:1(v/v) acetone/ dichloromethane and analyzed by GC/MS-EI-SIM 
(see GC/MS-EI-SIM analysis for B(a)P section for additional details). 
 
B(a)P:  Lung tissue preparation and extraction 
 
 A frozen 100 mg (+10%) posterior section of lung was weighed (Mettler 
Toledo, AG104) in a specimen vial.  Ice-cold Milli-Q water (0.500 mL) was added 
o the frozen tissue in a cold room (4°C), and immediately sonicated (Sonics 






B(a)P-d12 IS was then added to the samples. Calibrators were concurrently  
prepared by fortification of B(a)P and IS to 0.500 mL aliquots of analyte-free  
(blank) lung homogenates (aliquots were one part lung tissue to five parts  
water, w/v).  A liquid-liquid extraction was then performed.  Hexane (1.5 mL) 
was added to lung homogenate, then thoroughly vortexed, and centrifuged at 
3500 rpm for 4 mins.  This was performed a total of three times, then combined 
organic fractions were dried under a constant stream of nitrogen in a Zymark 
Turbovap® LV evaporator at 55°C. Residues were then reconstituted in 0.050 mL 
of 1:1 acetone/dichloromethane, transferred to an autosampler vial, and analyzed 
by GC/MS-EI- SIM (see GC/MS-NCI-SIM analysis for B(a)P section for additional 
details). 
 
B(a)P:  Plasma preparation and extraction 
 
To a 1 mL aliquot of plasma, B(a)P-d12 IS was added. Calibrators were 
concurrently prepared by fortification of B(a)P and IS to analyte-free (blank) rat 
plasma.  A liquid-liquid extraction was then performed according to the following 
procedure.  Hexane (1.5 mL) was added to each plasma sample, then thoroughly 
vortexed, and centrifuged at 3500 rpm for 4 mins.  This was performed a total of 
three times, then combined organic fractions were dried under a constant stream 
of nitrogen in a Zymark Turbovap® LV evaporator at 55°C. Residues were then 
reconstituted in 0.050 mL of 1:1 acetone/dichloromethane, transferred to an 
autosampler vial for analysis by GC/MS-EI- SIM (see GC/MS-EI-SIM analysis for 






Assays for BPT released from BPDE-protein adducts 
 
BPT:  Hair preparation and extraction 
Hair (100 mg (+10%)) was weighed out (Mettler Toledo, AG104) and 
[13C6]-BPT IS added. Calibrators were concurrently prepared by fortification of 
BPT and IS to analyte-free (blank) rat hair. To each hair sample, 2 mL of  200 
ug/mL Proteinase K in incubation buffer (50 mM Tris buffer, 5 mM calcium 
chloride, pH 8.5) was added to digest hair. Samples were then placed in a 
sonicator for 1 hr (~37°C), transferred to a 37°C water bath and allowed to 
incubate overnight (total time ~20 hrs). After cooling, approximately 0.25 g of 
sodium chloride (NaCl) was added to each sample, and a liquid-liquid extraction 
was then performed. Ethyl acetate (6 mL) was added to each hair digestion 
solution, which was then thoroughly vortex-mixed followed by centrifugation at 
3500 rpm for 4 mins. The liquid-liquid extraction was performed twice and then 
the combined organic fractions were placed in a Zymark Turbovap® LV 
evaporator at 55°C under a constant stream of N2 until dry. The residues were 
then derivatized by adding 50 uL of MSTFA and allowing for 15 mins reaction 
time in a hot block at 80°C. Samples, in MSTFA, were then transferred to 
autosampler vials for analysis by GC/MS-NCI-SIM (see GC/MS-NCI-SIM 
analysis for BPT section for additional details). 
 
BPT:  Hemoglobin preparation from whole blood and extraction 
 
Fresh whole blood from rats was centrifuged at 3500 rpm for 5 mins to 
separate plasma from red blood cells (RBCs).  The plasma was removed and 





then washed twice with equivalent volumes of 0.9% sodium chloride solution in 
Milli-Q water to remove any free, unbound BPT (from metabolism by epoxide 
hydrolase and/or water).  One volume of phosphate buffered saline (PBS) and 
two volumes of RBC lysis buffer were added to re-suspend the RBCs (e.g., 3 mL 
RBCs then 3 mL of PBS and 6 mL of RBC lysis buffer). This was done to keep 
volumes of reagents consistent between samples of differing volumes.  The 
samples were then gently shaken for 10 mins for lysis of RBCs, followed by 
centrifugation at 2000 rpm to pellet ghost membranes. The supernatant was 
removed from each sample, and six volumes of ice-cold acetone (with 0.015% 
hydrochloric acid) was slowly added, dropwise, to precipitate Hb. After 5 mins the 
samples were centrifuged to pellet the precipitated Hb, and the excess fluid was 
decanted.  The Hb pellet was then evaporated to dryness in a Zymark Turbovap® 
LV evaporator under a constant stream of nitrogen at 37°C and stored at -80°C 
until preparation for analysis. Hb (100 mg (+10%)) (prepared as described 
above) was weighed (Mettler Toledo, AG104) and IS added. Calibrators were 
concurrently prepared by fortification of BPT and IS to analyte-free (blank) rat Hb.  
After Hb isolation, hydrolysis of the Hb samples was performed as follows:  
Two milliliters of NANOpureTM water and 30 μL of 6 N hydrochloric acid to each 
Hb sample, tightly capped, and incubation in a water bath at 90°C for 3 hrs. 
Samples were allowed to cool, then approximately 0.25 g of sodium chloride was 
added to each sample. A liquid-liquid extraction was then performed. Ethyl 
acetate (6 mL) was added to each Hb hydrosylate, then thoroughly vortex-mixed, 





combined organic fractions were placed in a Zymark Turbovap® LV evaporator at 
52°C under a constant stream of N2 until dry. Samples were capped and stored 
at -20°C overnight, and extracted by SPE the following morning. Solid phase 
extraction (SPE) was performed by conditioning Waters C18 3cc columns with 
2.5 mL of methanol followed by 2.5 mL of NANOpureTM water.  The sample 
(reconstituted in a total volume of 2.5 mL of 50% aqueous methanol) was slowly 
loaded onto the column, and allowed to incubate for 5 mins.  The column was 
washed with 2.5 mL of NANOpureTM water, then 50% aqueous methanol and 
then dried for 5 mins under a vacuum pressure around 5 psi.  The samples were 
eluted from the column using two volumes of 2.5 mL 50:50 acetonitrile/methanol. 
The eluents were completely dried at 55°C in a Zymark Turbovap® LV evaporator 
under a constant stream of nitrogen.  MSTFA (50 μL) was added to the residues 
and 15 min reaction time was allowed in a hot block at 80°C. Samples were then 
transferred to autosampler vials for analysis by GC/MS-NCI-SIM (see GC/MS-
NCI-SIM analysis for BPT section for additional details).  
 
Evaluation of wash procedure for rat hair 
 
 Two hundred mg of rat hair (from one individual 160 mg/kg B(a)P dosed 
rat) was separated into three groups: Group 1)  Unwashed hair (n=2), Group 2) 
Shampoo washed hair (n=2), and 3) Dichloromethane wash hair (n=2).   For 
Group one (unwashed hair), 10 mg +10% of hair were weighed (Mettler Toledo, 
AG104) for each sample, then digested and extracted as described in the “B(a)P:  
Hair preparation and extraction” section in Materials and Methods section.  For 





solution was added to each sample, quickly vortex-mixed, and liquid portion 
decanted from hair.  Hair samples were then allowed to dry overnight at room 
temperature in the dark.  The following day, 10 mg +10% of hair were weighed 
for each sample, then digested and extracted as written above.  For Group 3 
(dichloromethane washed hair), 0.1 mL of dichlormethane was added to each 
sample, quickly vortex-mixed, and then decanted from hair.  Hair samples were 
then allowed to dry overnight at room temperature in the dark.  The following day, 
10 mg +10% of hair were weighed for each sample, then digested and extracted 
as previously described.   
 
GC/MS-EI-SIM analysis for B(a)P 
 
A Hewlett Packard  (HP) GC 6890 was fitted with a Agilent DB-5UI-MS 
capillary column (part no. 122-5535UI, 30.0 m x 250 μm x 0.25 μm nominal). The 
injector was operated in the pulsed splitless mode (injection pulse 40 psi until 0.2 
min, purge flow to split vent 30 mL/min at 0.75 min). The pressure of helium gas 
was programmed to 17.0 psi (total flow 33.8 mL/min). The inlet heater 
temperature was set at 300°C and the transfer line was set at 300°C.  The 
injection volume was 1 μL. The solvent delay was set at 3 mins. The initial oven 
temperature was set at 120°C for 1 min, then ramped to 250°C at 25°C/min A 2nd 
ramp to 320°C at 10°C /min followed, and then oven was held at 320°C for 3.5 
mins. The total run time equaled 16.7 mins.  An HP MS 5973 was used to 
perform selective ion monitoring (SIM) was used to detect B(a)P at m/z 252 and 
its fragment at m/z 126. B(a)P-d12 was detected at m/z 264. To quantitate the 





calibration curves from peak area ratios of target analyte and the corresponding 
internal standard over the concentration range.  
 
GC/MS-NCI-SIM analysis for BPT 
 
The same GC/MS system and column was used as stated in the GC/MS-
EI-SIM analysis. The injector was operated in the pulsed splitless mode (injection 
pulse 17.6 psi until 1.33 min, purge flow to split vent 30 mL/min at 1.75 mins). 
The pressure of helium gas was programmed to 24.3 psi (flow 2.2 mL/min, total 
flow 34.5 mL/min).  Ammonia reagent gas pressure was set at 17.0 mL/min The 
inlet heater temperature was set at 280°C.  The transfer line was set at 300°C.  
The injection volume was 2 μL and the solvent delay was set at 9.0 mins. The 
initial oven temperature was set at 120°C for 1 min, then ramped to 250°C at 
20°C/min A 2nd ramp to 300°C at 8°C /min followed. The total run time equaled 
13.75 mins. SIM was used to detect the derivatized BPT at m/z 446. The 
derivatized (13C6)-BPT internal standard was detected at m/z 452. To quantitate 
the results, ChemStation software (version: D.02.00.275) was used to generate 
calibration graphs from peak area ratios of target analyte and the corresponding 




Graph Pad Prism® software (version 5.01) (La Jolla, CA) was used to 
compare results from 40, 80, and 160 mg/kg dosed rats using a one-way ANOVA 
and a Newman-Keuls posthoc test for:  1) B(a)P concentrations in hair of the 40, 





160 mg/kg dosed rats, 3) BPT released from BPDE-Hb adducts in the 40, 80, 
and 160 mg/kg dosed rats, 4) B(a)P concentrations in rat lung of the 40, 80, and 
160 mg/kg dosed rats, and 5) B(a)P concentrations in rat plasma of the 40, 80, 
and 160 mg/kg dosed rats.  A Student’s t-test was used to compare B(a)P and 
BPT concentrations between pigmented and nonpigmented rat hair. Spearman 
nonparametric correlation tests were used to measure the strength of the 
association between the following: 1) B(a)P concentrations in rat hair and the 
positive control (BPDE-Hb adducts), 2) BPT concentrations in rat hair and the 
positive control (BPDE-Hb adducts), 3) B(a)P concentrations in plasma and lung 










 Figure 2.2 shows representative chromatograms for an extracted 0.25  
ng/mg B(a)P calibration standard (lowest standard in curve) and an extracted 
blank rat hair sample.  The assay was determined to be linear from 0.25 to 100 
ng/mg. The lower limit of quantitation (LLOQ) and upper limit of quantitation 
(ULOQ) were 0.25 and 100 ng/mg, respectively. The coefficient of variation (CV) 
for the intra- and interassay accuracy and imprecision were less than or equal to 
10% (Table 2.1). 
 The intra- and interaccuracy and imprecision data were determined by  


















Figure 2.2 Representative ion chromatograms from (A) extracted analyte-free 
(blank) rat hair sample and (B) an extracted B(a)P-fortified (0.25 ng/mg, LLOQ) 
rat hair sample.  The small peak for B(a)P in extracted blank rat hair is due a 
small impurity present in the IS B(a)P-d12 (98.4% pure) (calculated concentration 
for this sample is below the LLOQ). There is no peak for B(a)P in blank rat hair 
without IS (data not shown).  Analyte retention time (RT) is on the x-axis and 
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Accuracy, imprecision, LLOQ, and ULOQ of B(a)P-fortified rat hair 
 





Concentration % of Target %CVb 
  ng/mg   pg/mg     
Intraassay 
     
 
0.75 5 0.72 95.5 4.9 
 
40.00 5 42.14 105.4 1.2 
 
80.00 5 83.36 104.2 5.4 
Interassay 
     
 
0.75 15 0.71 95.2 10.2 
 
40.00 15 43.91 109.8 4.8 
 
80.00 15 88.32 110.4 6.8 
      
 
    
      





Concentration % of Target %CVb 
  pg/mg   pg/mg     
LLOQ 
     
 
0.25 5 0.22 86.0 6.0 
      ULOQ 
     
 
100.00 5 96.40 96.4 3.5 
            
 
 
a Number of quality control replicate samples used 










manufacturer from that used to make the calibration curve standards.  Accuracy 
was calculated by dividing the observed concentration by the target 
concentration. This value was then multiplied by 100 to obtain a percentage. The 
percent CV was calculated by dividing the standard deviation of the group by the 
mean observed concentration of the group.  This value was then multiplied by 
100 to obtain a percentage. The percent CV calculated from the mean observed 
concentrations of samples tested is an estimate of imprecision of the assay.   
The intraassay accuracy and imprecision were determined by analyzing 
five replicate samples of analyte-free rat hair fortified with known amounts of 
B(a)P (0.75, 40, and 80 ng/mg) within a single analytical batch on the same day.  
The intraassay accuracy ranged from 95.5-105.4% of the theoretical target 
concentrations. The intraassay imprecision ranged from 1.2-5.4%. 
 The accuracy and imprecision for the interassay were determined by 
comparing calculated concentrations from replicates (n=5 for each concentration, 
total n=15) of B(a)P-fortified rat hair samples at 0.75, 40, 80 ng/mg for three  
separate analytical batches on three separate days.  The intraassay accuracy 
ranged from 95.2-110.4% of the theoretical target concentrations. The intraassay 
imprecision ranged from 4.8-10.2%. 
The LLOQ was evaluated by the analysis of five replicates of B(a)P  
fortified analyte-free rat hair at 0.25 ng/mg.  The average accuracy for these 
samples was 86.0%, and the imprecision was 6.0%. 
The ULOQ was evaluated by the analysis of five replicates of B(a)P- 





these samples was 96.4%, and the imprecision was 3.5%. 
 
Lung 
 Figure 2.3 shows representative chromatograms for an extracted 12.5 
pg/mg B(a)P calibration standard (lowest standard in curve) and an extracted 
blank rat lung sample.  The assay was determined to be linear from 12.5 to 1000 
pg/mg. The LLOQ and ULOQ were 12.5 and 1000 pg/mg respectively. The 
coefficient of variation (CV) for the intra- and interassay accuracy and 
imprecision were less than or equal to 15% (Table 2.2). 
 The intra- and interaccuracy and imprecision data were determined by 
analysis of samples that were prepared with a stock solution from a different 
manufacturer from that used to make the calibration curve standards.  
The intraassay accuracy and imprecision were determined as previously 
described. Analyte-free lung samples were fortified with B(a)P at 37.5, 400, and 
750 pg/mg and analyzed within a single batch.  The intraassay accuracy ranged 
from 100.7-114.8% of the theoretical target concentrations. The intra- assay 
imprecision ranged from 2.6-14.8%. 
  The accuracy and imprecision for the interassay were also determined as  
previously described. Analyte-free lung samples were fortified with B(a)P 37.5,  
400, 750 pg/mg and analyzed in three separate analytical batches on three 
separate days.  The intraassay accuracy ranged from 103.2-115.6% of the 
theoretical target concentrations. The intraassay imprecision ranged from 2.8- 
14.1%. 

















Figure 2.3 Representative ion chromatograms from (A) extracted analyte-free 
(blank) rat lung sample and (B) an extracted B(a)P-fortified (12.5 pg/mg, LLOQ) 
rat lung sample. The small peak for B(a)P in extracted blank rat hair is due a 
small impurity present in the IS B(a)P-d12 (98.4% pure) (calculated concentration 
for this sample is below the LLOQ). There is no peak for B(a)P in blank rat lung 
without IS (data not shown).   Analyte retention time (RT) is on the x-axis and 















































Io n  2 5 2 .0 0  (2 5 1 .7 0  to  2 5 2 .7 0 ):  0 1 1 1 1 1 -0 2 .D \ d a ta .m s



























































Io n  2 5 2 .0 0  (2 5 1 . 7 0  t o  2 5 2 . 7 0 ):  0 1 1 1 1 1 -0 4 .D \ d a t a . m s
































Accuracy and imprecision of B(a)P-fortified rat lung tissue. 





Concentration % of Target %CVb 
  pg/mg   pg/mg     
Intraassay 
     
 
37.5 5 43.1 114.8 4.2 
 
400.0 5 413.1 103.3 2.6 
 
750.0 5 805.8 100.7 14.8 
Interassay 
     
 
37.5 15 43.3 115.6 4.4 
 
400.0 15 412.6 103.2 2.8 
 
750.0 15 808.9 107.9 14.1 
            
      





Concentration % of Target %CVb 
  pg/mg   pg/mg     
LLOQ 
     
 
12.5 5 14.6 117.0 1.9 
      ULOQ 
     
 
1000.0 5 1031.4 103.1 2.6 
            
 
 
a Number of quality control replicate samples used 










mean average accuracy for the LLOQ was 117.0% with an imprecision of 1.9%.  




 Figure 2.4 shows chromatograms for an extracted 25 ng/mL B(a)P 
calibration standard (lowest standard in curve) and an extracted blank rat plasma 
sample.  The assay was determined to be linear from 25 to 3200 ng/mL. The 
LLOQ and ULOQ were 25 and 3200 ng/mL, respectively. The coefficient of 
variation (CV) for intra- and interassay accuracy and imprecision were less than 
20% (Table 2.3). 
 The intra- and interaccuracy and imprecision data were determined by 
analysis of samples that were prepared with a stock solution from a different 
manufacturer from that used to make the calibration curve standards.   
The intraassay accuracy and imprecision were determined as previously 
described. Analyte-free plasma samples were fortified with B(a)P at 75, 1500, 
and 2750 ng/mL and analyzed within a single batch.  The intraassay accuracy 
ranged from  94.2-96.4% of the theoretical target concentrations. The intraassay 
imprecision ranged from 5.8-20.0%. 
 The accuracy and imprecision for the interassay were determined as 
previously described. Analyte-free plasma samples were fortified with B(a)P at 
75, 1500, 2750 ng/mL and analyzed in three separate analytical batches on three  
separate days.  The interassay accuracy ranged from 94.1 - 98.8% of the 



















Figure 2.4 Representative ion chromatograms from (A) extracted analyte-free 
(blank) rat plasma sample and (B) an extracted B(a)P-fortified (25 ng/mL, LLOQ) 
rat plasma sample. The small peak for B(a)P in extracted blank rat hair is due a 
small impurity present in the IS B(a)P-d12 (98.4% pure) (calculated concentration 
for this sample is below the LLOQ). There is no peak for B(a)P in blank rat 
plasma without IS (data not shown).  Analyte retention time (RT) is on the x-axis 
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Accuracy and imprecision of B(a)P-fortified rat plasma. 





Concentration % of Target %CVb 
  ng/mL   ng/mL     
Intraassay 
     
 
75 5 70.7 94.2 5.8 
 
1500 5 1450 96.4 5.2 
 
2750 4* 2600 94.4 20.0 
Interassay 
     
 
75 15 74.1 98.8 12.7 
 
1500 15 1415.2 94.3 4.7 
 
2750 12* 2588.3 94.1 18.0 
      
 
    
      





Concentration % of Target %CVb 
  ng/mL   ng/mL     
LLOQ 
     
 
25 5 27.4 109.5. 10.4 
      ULOQ 
     
 
3200 5 3184.3 99.5 3.0 
      
 
    
 
 
a Number of quality control replicate samples used 
b CV= coefficient of variation 
*Sample(s) in set was considered an outlier and therefore not used in 








The LLOQ and ULOQ were evaluated as described previously. The mean 
accuracy the LLOQ was 109.5% with a imprecision of 10.4%. The mean  
accuracy for the ULOQ was 99.5% with a imprecision of 3.0%. 
 




 Figure 2.5 shows chromatograms for an extracted 5 pg/mg BPT 
calibration standard (lowest standard in curve) and an extracted blank rat hair 
sample.  The assay was determined to be linear from 5 to 40 pg/mg. The LLOQ 
and ULOQ were 5 and 40 pg/mg, respectively. The coefficient of variation (CV) 
for the intra- and interassay accuracy and imprecision were less than 10%  
(Table 2.4). 
The stock and intermediate solutions for accuracy and imprecision for 
intra- and interassay samples were made by the quality control officer, or other 
Center for Human Toxicology personnel (since only one supplier existed for BPT 
at the time of this research). The stock and intermediate solutions used to make  
the calibration standards were prepared by Sarah Campbell.  Accuracy and 
imprecision were calculated as previously described.  
The intraassay accuracy and imprecision were determined as previously 
described. Analyte-free rat hair samples were fortified with BPT at 15, 25, and 30 
pg/mg and analyzed within a single batch. The intraassay accuracy ranged from 
95.4 - 98.0% of the theoretical target concentrations. The intraassay imprecision 
ranged from 5.9 - 9.7%.  


















Figure 2.5 Representative ion chromatograms from (A) extracted analyte-free 
(blank) rat hair sample and (B) an extracted BPT-fortified (5 pg/mg, LLOQ) rat 
hair sample. Samples shown were also fortified with the internal standard (13C6)-
BPT. Analyte retention time (RT) is on the x-axis and signal intensity on the y-
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Accuracy and imprecision of BPT-fortified rat hair. 








  pg/mg   pg/mg     
Intraassay 
     
 
15 5 14.7 98.0 9.7 
 
25 5 24.3 97.2 6.3 
 
35 4* 33.4 95.4 5.9 
Interassay 
     
 
15 15 14.7 97.9 6.8 
 
25 15 24.0 95.9 5.2 
 
35 14* 34.0 97.3 4.7 
            
      








  pg/mg   pg/mg     
LLOQ 
     
 
5 5 4.2 84.0 10.2 
      ULOQ 
     
 
40 5 39.0 97.5 9.7 
            
 
 
a Number of quality control replicate samples used 
b CV= coefficient of variation 










previously described. Analyte-free hair samples were fortified with BPT at 15, 25, 
35 pg/mg and analyzed in three separate analytical batches on three  
separate days.  The intraassay accuracy ranged from 95.9 - 97.9% of the 
theoretical target concentrations. The intraassay imprecision ranged from 4.7 - 
6.8%. 
The LLOQ and ULOQ were evaluated as described previously. The mean 
accuracy for the LLOQ was 84.0% with a imprecision of 10.2%. The mean 




 Figure 2.6 shows chromatograms for an extracted 2.5 pg/mg BPT 
calibration standard and an extracted blank rat Hb sample.  The assay was  
determined to be linear from 2.5 to100 pg/mg. The LLOQ and ULOQ were 2.5 
and 100 pg/mg, respectively. The coefficient of variation (CV) for the intra- and 
interassay accuracy and imprecision were less than 10% (Table 2.5). 
The stock and intermediate solutions for accuracy and imprecision for 
intra- and interassay samples were made by the quality control, or other Center 
for Human Toxicology personnel (since only one supplier exists for BPT). The 
stock and intermediate solutions used to make the calibration standards were 
prepared by Sarah Campbell.   
The intraassay accuracy and imprecision were determined as previously 
described. Analyte-free Hb samples were fortified with BPT at 7.5, 37.5, and 80 
pg/mg and analyzed within a single batch.  The intraassay accuracy ranged  



















Figure 2.6 Representative ion chromatograms from (A) extracted analyte-free 
(blank) rat Hb sample and (B) an extracted BPT-fortified (2.5 pg/mg, LLOQ) rat 
Hb sample. Samples shown were also fortified with the internal standard (13C6)-
BPT. Analyte retention time (RT) is on the x-axis and signal intensity on the y-
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Accuracy and imprecision of BPT-fortified rat Hb. 





Concentration % of Target %CVb 
  pg/mg   pg/mg     
Intraassay 
     
 
7.5 5 7.3 97.3 6.1 
 
37.5 5 35.6 95.0 0.9 
 
80.0 5 76.7 95.9 0.5 
Interassay 
     
 
7.5 15 7.3 97.9 5.5 
 
37.5 15 35.5 94.6 1.5 
 
80.0 13* 76.9 96.1 1.0 
            
      





Concentration % of Target %CVb 
  pg/mg   pg/mg     
LLOQ 
     
 
2.5 4** 3.0 121.2 20.0 
      ULOQ 
     
 




    
 
a Number of quality control replicate samples used 
b CV= coefficient of variation 
*Two samples in group did not get injected 
**Sample in group was considered an outlier due to poor chromatography and 









imprecision ranged from 0.5 - 6.1%. 
The accuracy and imprecision for the interassay were determined as 
previously described. Analyte-free Hb samples were fortified with BPT at 7.5, 
37.5, 80 pg/mg and analyzed in three separate analytical batches on three  
separate days.  The intraassay accuracy ranged from 94.6 - 97.9% of the 
theoretical target concentrations. The intraassay imprecision ranged from 1.0 - 
5.5%. 
The LLOQ and ULOQ were evaluated as described previously. The mean 
accuracy for the LLOQ was 121.2% with a imprecision of 20.0%. The mean 
accuracy for the ULOQ was 98.7% with a imprecision of 2.9%. 
 
Results from animal experiments 
 
 
Incorporation of B(a)P into rat hair 
 Baseline (Day 0) rat hair samples, as well as Day 14 hair samples from 
control rats, both analyzed using the developed methods, were below the LLOQ 
for B(a)P (data not shown).  Figure 2.7 shows the mean + SEM (standard error of  
the mean) concentrations for B(a)P detected in pigmented hair from rat 
administered 40 mg/kg, 80mg/kg, or 160 mg/kg B(a)P. 
 The concentration of B(a)P detected in rat hair at Day 14 increases in a 
dose-dependent manner,  ranging from nondetected to 3.3 ng/mg.  Specifically, 
hair concentrations of B(a)P were 0.10 + 0.06 ng/mg for 40 mg/kg dosed rats, 0.7 
+ 0.2 ng/mg for the 80 mg/kg dosed rats, and 1.1 + 0.3 ng/mg for 160 mg/kg 



















Figure 2.7 Concentrations of B(a)P in Rat Hair.  A)  Hair concentrations of B(a)P 
in the hair of B(a)P dosed rats. B(a)P concentrations in rat hair increase in a 
dose-dependent manner .  B)  B(a)P concentrations in pigmented and 
nonpigmented rat hair from 160 mg/kg dosed rats.  B(a)P concentrations in 
pigmented and nonpigmented rat hair do not statistically differ. Error bars 























































































pigmented and nonpigmented rat hair from animals dosed at 160 mg/kg (Figure 
2.7). At this dose the mean (+ SEM) for B(a)P concentration for pigmented hair 
from 160 mg/kg dosed animals  was 1.0 + 0.3 ng/mg and 1.0 + 0.3 ng/mg in 
nonpigmented. 
 
Incorporation of BPT into rat hair 
 
 Baseline (Day 0) rat hair samples, as well as Day 14 hair samples from 
control rats, were all below the LLOQ for BPT (data not shown).  Figure 2.8 
shows the mean + SEM (standard error of the mean) concentrations for BPT 
released from pigmented rat hair after the administration of 40 mg/kg, 80mg/kg, 
and 160 mg/kg B(a)P. The concentration of BPT detected in rat hair increases in 
a dose- dependent manner;  The measured concentrations of BPT in the hair of  
B(a)P dosed rats at Day 14 ranged from 3.6 to 62.6 pg/mg.  Hair concentrations 
of BPT released were 7.3 + 0.6 pg/mg for 40 mg/kg dosed rats, 9.9 + 0.7 pg/mg 
for the 80 mg/kg dosed rats, and 42.1 + 4.1 pg/mg for 160 mg/kg dosed rats.  
There was a significant difference in the concentration of BPT released from 
pigmented and nonpigmented rat hair after administration of 160 mg/kg B(a)P 
(Figure 2.8). The mean (+ SEM) for BPT concentrations released from hair from 
160 mg/kg B(a)P-dosed animals was 41.5 + 0.3 pg/mg and 26.3 + 0.3 pg/mg in 
pigmented and nonpigmented hair, respectively. 
 
Positive control results  
 BPDE-Hb adducts were selected as the positive control for these 


















Figure 2.8 Concentrations of BPT in Rat Hair.  A)  BPT released from hair of 
B(a)P dosed rats. BPT concentrations released from rat hair increase in a dose-
dependent manner. However, results from 40 mg/kg and 80 mg/kg are not 
statistically different from each other, whereas results between 80 mg/kg and 160 
mg/kg, and 40 mg/kg and 160 mg/kg statistically differ.  B)  BPT released from 
pigmented and nonpigmented from 160mg/kg dosed rats.  BPT released from 
pigmented and nonpigmented are statistically different.  Error bars represent the 





























































































characterized as a biomarker of B(a)P exposure.  These adducts are associated 
with toxicity, and account for cumulative exposures over the life-span of an  
erythrocyte (120 days). BPDE-protein adducts have been studied in blood 
proteins (e.g., Hb, albumin) [60, 121-124] and BPDE-DNA adducts in several 
different tissues [125-129].  While DNA adducts have provided useful information 
regarding carcinogenicity, major limitations exist: 1) BPDE-DNA adducts are 
subject to enzymatic repair by excision repair enzymes;  2) There is a high 
frequency (as much as 70%) of BPDE-DNA samples in which no adducts are 
found. To combat these issues, we chose the BPDE-Hb adduct, rather than the 
DNA adduct, as it is much more abundant and not subject to enzymatic repair. 
BPDE-Hb adducts are commonly used as surrogates for DNA adducts in order to  
assess diseases progression and cancer risk [60] . 
 As expected, we saw a dose-dependent increase in the BPDE-Hb adduct 
(measured by BPT released) (Figure 2.9) from the blood of B(a)P dosed rats.  Hb 
samples from control rats were at or below the LLOQ for BPT, with the exception 
of one rat at about three times the LLOQ. However, the result for this rat was still 
below the concentrations observed in our lowest B(a)P dosed group.  
 The major source for B(a)P in nonsmokers is via the ingestion and 
inhalation of B(a)P from foods (especially charbroiled foods), water, and air [76]. 
Rats from this study may also be exposed to B(a)P from similar sources.  We 
tested the corn oil used for making the dosing solutions and did not find 
detectable levels of B(a)P (data not shown).  BPDE-Hb adducts can be detected 

















Figure 2.9 Positive control results for B(a)P dosed rats.  A)  BPDE-Hb adduct 
concentrations from B(a)P dosed rats.  BPDE-Hb adducts increase in a dose-
dependent manner.  B)  Spearman correlation test results for the comparison of 
B(a)P in rat hair and BPDE-Hb adducts.  Each dot represents a single rat. There 
is a significant correlation between concentrations of B(a)P detected in hair and 
our positive control. (Data from rats that were nondetected for B(a)P in hair are 
not included.)  C)  Spearman correlation test results for the comparison of BPT 
released from rat hair and BPDE-Hb adducts.  There is a significant correlation 
between BPT released from hair and our positive control.  D) Spearman 
correlation test results for the comparison of B(a)P and BPT released from rat 
hair.  There is a significant correlation between B(a)P and BPT released from rat 
hair.  (Data from rats that were nondetected for B(a)P in hair are not included.)  














































































































































































unexposed control rats is not unusual.   Figure 2.9 A shows the mean + SEM 
concentrations for BPT released from the Hb of 40 mg/kg, 80mg/kg, and 160 
mg/kg dosed rats. The measured concentrations of BPDE-Hb adducts in the 
B(a)P dosed rats ranged from 11.9 to 79.4 pg/mg.  The mean + SEM BPDE-Hb 
adduct concentrations were 15.7. + 1.1 pg/mg for 40 mg/kg dosed rats, 33.4 + 
4.0 pg/mg for the 80 mg/kg dosed rats, and 55.4 + 4.0 pg/mg for 160 mg/kg 
dosed rats.   
 We compared the concentrations of B(a)P and BPT released from rat hair 
with the results from our positive control (BPDE-Hb adducts) to determine 
whether there was a positive association between the measures (Figure 2.9, 
panels B and C). There was a significant correlation between concentrations of 
B(a)P detected in hair and the presence of BPDE-Hb adducts from blood (our 
positive control, p<0.01).  There was a more robust significant correlation 
between BPT released from hair and our positive control (p<0.0001).  We also 
determined there was a significant correlation between concentrations of B(a)P in 
rat hair and BPT released from rat hair (Figure 2.9, panel D). 
 
B(a)P in lung tissues of dosed rats 
 
 The measured concentration of B(a)P in lung tissue from corn oil-treated 
control rats, were all below the LLOQ (data not shown).  Figure 2.10 shows the 
mean + SEM concentrations for B(a)P detected in lung tissue collected on Day 
14 from 40 mg/kg, 80mg/kg, and 160 mg/kg B(a)P dosed rats. The results 
represented in Figure 2.10 are therefore due to the retention of B(a)P in the lung 
















































Figure 2.10  B(a)P remaining in rat lung tissues at Day14.  The concentration of 
B(a)P detected in rat lung tissues increases in a dose-dependent manner, with a 
sharp increase in the concentration between the 80 mg/kg and 160 mg/kg doses 
animals.  Solid horizontal bars represent the mean and the vertical error bars 






increases in a dose-dependent manner, with a sharp increase in the 
day). The mean concentration of B(a)P detected in rat lung tissues at Day 14  
concentration between the 80 mg/kg and 160 mg/kg dosed animals.  Specifically, 
the measured concentrations of B(a)P remaining in the lung ranged from 
nondetected to 85.1 ng/mg. Then mean + SEM lung tissue concentrations of 
B(a)P were 0.1 + 0.1 ng/mg for 40 mg/kg dosed rats, 0.8 + 0.4 ng/mg for the 80 
mg/kg dosed rats, and 23.4. + 8.4 ng/mg for 160 mg/kg dosed rats, respectively.   
 
B(a)P in the plasma of dosed rats 
 
 The measured concentration of B(a)P in plasma from corn oil control 
treated rats, were all below the LLOQ (data not shown).  Figure 2.11 shows the  
mean + SEM concentrations for B(a)P detected in plasma from 40 mg/kg, 
80mg/kg, and 160 mg/kg dosed rats. The results in Figure 2.11 represent  
circulating B(a)P concentrations after dosing had been discontinued seven days 
earlier. The concentrations of circulating B(a)P at Day 14 increases in a dose-
dependent manner, with a sharp increase in the concentration between the 80  
mg/kg and 160 mg/kg dosed animals (as seen in B(a)P concentrations in the 
lung tissues, Figure 2.10).  The measured concentrations of B(a)P remaining in 
the plasma ranged from nondetected to 33.2 ug/mL.  The mean + SEM plasma 
concentrations of B(a)P were 7.0 + 5.3 ng/mL for 40 mg/kg dosed rats, 106.3 + 
53.1 ng/mL for the 80 mg/kg dosed rats, and 6926 + 3400 ng/mL for 160 mg/kg 
dosed rats. There was no correlation between concentrations of B(a)P circulating 


















































Figure 2.11  B(a)P concentrations circulating in rat plasma at Day 14.  The 
circulating concentrations of B(a)P detected in rat plasma increases in a dose-
dependent manner, with a sharp increase in the concentration between the 80 
mg/kg and 160 mg/kg dosed animals (as seen in the rat lung tissue).  Solid 







There was a significant correlation between concentrations of B(a)P remaining in  
lung tissue and circulating B(a)P concentrations in the plasma (Figure 2.12).  
 
 
Wash experiment on rat hair 
 
 The results from an initial wash experiment with B(a)P incorporated in rat 
hair using a shampoo solution and an organic solvent (dicloromethane) are 
shown in Figure 2.13.  The mean + SEM concentration for B(a)P in the 
unwashed hair hair sample was 0.49 ng/mg.  In contrast, the mean + SEM 
concentration for B(a)P in the hair washed with either shampoo or 
dichlormethane were 0.10 pg/mg and 0.13 pg/mg, respectively.  Since 
performing a wash greatly reduced the concentration of B(a)P several fold from 
what had been incorporated into the rat hair shaft, we chose not to perform 




 The described GC/MS methods in this chapter are sensitive and specific, 
and were developed 1) to detect B(a)P in hair, lung, and plasma, 2) BPDE-
induced adducts from the hair, and 3) hemoglobin of B(a)P dosed rats.  Using 
these methods, we determined that B(a)P and BPDE-protein adducts can be 
detected in rat hair and are incorporated into hair in a dose-dependent manner. 
To our knowledge, the detection of these compounds in rat hair is a novel finding.  
Whereas B(a)P concentrations in rat hair do not statistically differ between 
pigmented vs. nonpigmented rat hair, BPDE-protein adduct concentrations in 





















































































Figure 2.12 Spearman correlation test results for the comparison of B(a)P in 
plasma and lung at Day 14. Each dot represents a single rat.  There is a 
significant correlation between concentrations of B(a)P in the plasma and lung. 
(Data from rats that were nondetected for B(a)P in plasma and lung were not 


























































Figure 2.13  Results from the washing of B(a)P incorporated rat hair. These 
results demonstrate that washing hair with a 10% aqueous shampoo wash 
solution and dichloromethane (DCM) greatly reduce the detectable amount of 









and BPDE-protein adduct hair concentrations correlate to concentrations of the  
positive control (the extensively studied and well-characterized BPDE-Hb adduct) 
using a Spearman’s correlation test.  This demonstrates that these novel hair 
biomarkers may provide a useful tool to monitor B(a)P exposure in many different 
settings. The studies presented in this chapter were used to support our research 
on the incorporation of B(a)P and BPDE-protein adducts into human hair 
(Chapter 4), and their use as biomarkers of B(a)P exposure in smokers and 
nonsmokers. 
 
Possible mechanisms of B(a)P and BPDE-protein 
 
adduct incorporation in hair 
 
 No published data have previously been reported for the identification of 
B(a)P or BPDE-protein adducts in rat hair.  The actual mechanisms whereby 
these novel biomarkers incorporate into hair remains to be elucidated, and 
although it was not the focus of this dissertational research, the results from our 
rat studies support a passive diffusion model of incorporation (detailed in the 
Introduction of this chapter).  In conjunction this model, we hypothesize that 
B(a)P passively diffuses from the bloodstream at the base of the follicle to the 
hair forming cells, and then becomes incorporated into the growing hair shaft.  
Furthermore, we also hypothesized the electrophilic reactive intermediate BPDE 
is formed by the metabolism of B(a)P in the follicular cells of the hair bulb by 
CYP450’s and epoxide hydrolase enzymes. (The metabolism of B(a)P in hair 
follicles has been previously described [130-132]).  BPDE would then react to 





involve the formation of a covalent bond between the epoxide of BPDE and the 
thiol group on the very abundant cysteine residue in hair. There is strong 
evidence that BPDE binds to cysteine residues in intracellular proteins, and thiol 
groups in general are known to covalently bind with epoxides [133].  Morrison et 
al. have demonstrated with in vitro studies that depletion of thiol groups in 
hepatocytes leads to an increase in BPDE-protein adduct concentrations [134].  
Several studies have also addressed that the nucleophile glutathione, which 
contains a cysteine and is known to detoxify BPDE, plays a critical role in 
preventing the carcinogenesis of BPDE [135]. Also, it has been demonstrated 
that N-acetyl cysteine reduces, or eliminates, BPDE-adducts in the lung [136]. 
BPDE and reaction with acidic amino acids by ester linkage is also supported 
since upon proteolysis of adducted proteins tetrols are released.  This has been 
previously described with BPDE’s reaction mainly by alkylation of the amino acid 
aspartate number 47 (on its α side chain) in human Hb [98].  Other possible 
amino acid side chains in hair proteins that may participate in BPDE binding 
include: amines, carboxyaminde, carboxyl guandidine, hydroxyl, imidazole, 
indole, phenol, and sulfhydryl groups.   
In the deep compartment and multicompartment models, other routes of 
entry contribute to xenobiotic incorporation into hair.  These routes include 
exposure through sweat and sebum excretions, as well as from external 
environmental contaminants.  However, since rats only have sweat glands on the 
digital, palmar, and plantar pads of their feet, sweat is not a likely route of B(a)P 





contrast, secretions of these compounds via sebum cannot be ruled out as a 
possible route of incorporation.  Like the hair follicle, sebaceous glands are 
nourished by a dense network of capillaries though which xenobiotic can diffuse. 
Due to its highly lipophilic nature, B(a)P would likely accumulate in the sebum 
excreted from these glands. Sebaceous glands in the rat have CYP450s and 
other enzymes that have also been demonstrated to metabolize B(a)P [137].  
Whether BPDE-protein adducts are formed in the sebaceous gland and then 
discharged through its canal in connection with the hair follicle, or whether BPDE 
itself is transferred via the canal to react with proteins of the growing hair shaft 
remains to be elucidated.  
For the melainin-binding model, pigment content is considered an 
important feature in the incorporation of xenobiotics into hair.  Since certain drugs 
and xenobiotics have high affinities for melanin, the amount of melanin present in  
hair would have effects on the concentration found in different colors of hair.  
Since B(a)P is known to bind to melanin in vitro (including melanin in hair 
follicles) [44, 45, 138], we hypothesized that B(a)P would be incorporated to a 
greater extent in pigmented vs. nonpigmented rat hair.  This, however, was not 
the case for the neutral B(a)P compound, but may be playing a role in the 
incorporation of  BPDE-protein adducts.  Concentrations of BPDE-protein 
adducts were about 1.6 times higher in pigmented vs. nonpigmented rat hair.  
The electrophilicity of BPDE and/or the functional groups present (i.e. epoxide 
and hydroxyl) on the BPDE molecule are most likely are contributing to the 





As previously mentioned, there is general concern over hair analyses and 
confounding effects of external contamination, especially with smoked drugs. To 
limit potential sources of contamination in the present studies, rats were 
individually housed (to prevent social grooming) in hanging wire cages (to 
prevent contamination of the coat from bedding) and hair was only collected from 
areas where the animal would not be able to self-groom. Furthermore, since 
BPDE and BPT are metabolites of B(a)P and only synthesized in the body, 
contamination of hair with these compounds was unlikely to contribute to the 
findings in our studies.  We did perform an initial wash experiment with B(a)P 
incorporated rat hair using dichloromethane and a 10% aqueous shampoo 
solution (results shown in Figure 2.13).  Since performing a wash greatly reduced 
the concentration of B(a)P several fold from what had been incorporated into the 
rat hair shaft, we chose not to perform washes on any of the samples. 
 
Limitations of analysis for BPDE-protein  
 
adducts in hair 
 One caveat of measuring BPT released from hair, as evidence of a BPDE 
bound protein adduct, is that the analysis may also be measuring BPT as a 
metabolite from the further metabolism of BPDE by epoxide hydrolase and/or 
water.  Additionally, since enzymatic hydrolysis was used during the sample 
preparation, it is also possible that BPT may be released from BPDE conjugates 
such as BPDE-glutathione, BPDE-glucuronide and BPDE-sulfate conjugates.  
Given that hair is a solid structure comprised mostly of proteins, it would be 





proteins themselves.  Further research is needed to elucidate the percentage of 
free BPT vs. BPT released directly from BPDE-protein adducts in hair.  
 
 
Positive correlation of hair biomarkers and  
BPDE-Hb adducts 
We compared the concentrations of B(a)P and BPDE-protein adducts 
from rat hair with the results from our positive control (BPDE-Hb adducts) to 
determine whether there was a positive association between these measures 
(Figure 2.9, panel B). There was a significant correlation between the 
concentrations of B(a)P detected in the hair and our positive control (p<0.0147).  
There was an even more robust correlation between BPT released from hair and 
our positive control (p<0.0001).  Since the BPDE-Hb adduct has been thoroughly 
investigated and characterized [121-123, 139-141], and demonstrates that known 
adduct formation has occurred, our novel hair biomarkers presented in this 
chapter show great promise for assessing toxic B(a)P exposure. 
 
Plasma and lung B(a)P concentrations 
 
These studies did not find a correlation between concentrations of B(a)P 
or BPDE-protein adducts in hair and the concentrations of B(a)P remaining in the 
lung or plasma at Day 14.  However, hair concentrations are considered a 
cumulative marker of exposure, whereas concentrations in the plasma or lung 
would represent an acute exposure, so the lack of correlation was not completely 
unexpected. The concentrations of B(a)P that remained in the lung, and that 





lung’s inability to clear the high doses of B(a)P that were given and the high 
volume of distribution of B(a)P itself. The accumulation of B(a)P in rat lung has 
been previously described even after lower doses [74, 75, 142], and may be due 
to the substantially lower abundance of CYP450s in the lung to metabolize B(a)P 
in comparison with the liver [142].  Lung-mediated elimination of xenobiotic 
compounds presents toxicological and pharmacological important aspects, and 
the accumulation of B(a)P we observed in the lungs may be closely related to its 
toxic effects.  A future goal would be to elucidate whether concentrations of 
BPDE-protein adducts in the hair have a relationship to concentrations of BPDE-
protein adducts formed in the lung of our B(a)P dosed rats. 
In conclusion, the results presented in this chapter show great promise for 
biomonitoring of B(a)P exposure by means of these novel hair biomarkers. While 
the incorporation of B(a)P and BPDE-protein adducts may occur through multiple 
different mechanisms, and at various periods during hair growth, more research 
is needed to elucidate the mechanisms surrounding B(a)P and  BPDE-protein 
adduct incorporation into hair.  






















Route of B(a)P administration 
The pattern of pulmonary injury varies for inhaled toxicants compared to 
systemically and i.p administered toxicants. We chose to administer B(a)P by i.p. 
injection because it is simple, easily controlled, and provides an exact known 
dosage. It has also been demonstrated that i.p. administration of B(a)P is 
effective at inducing lung toxicities such as tumors and inflammation [143-146].  
We did not use inhalation delivery for several reasons:  1)  Volatile and 
semivolatile compounds, such as B(a)P, are poor candidates for inhalation 
toxicological dose-response studies due to their loss during the exposure 
process and poor reproducibility, which is prohibitory in the validation of fume 
concentrations [64, 73];  2)  High doses of B(a)P are not achievable by inhalation; 
3) Rodents undergo avoidance reactions when exposed to an inhalant;  4)  Given 
that rodents are obligatory nose breathers, and do not inhale the way humans 
do, this has differential effects in the dynamics of particle deposition in the rat’s 





histological changes that are independent of the administered toxicant.   
 
B(a)P and pulmonary toxicity 
 
The mammalian lung consists of more than 40 distinctive cell types. In 
general however, pneumotoxins select only six of these cell types as targets: 
type I and type II alveolar epithelial cells, capillary endothelial cells, pulmonary 
alveolar macrophages, ciliated bronchiolar epithelial cells, and clara cells 
(nonciliated bronchiolar epithelial cells). It is thought that the patterns of toxicity 
seen in the lung after xenobiotic exposure reflect the differences in formation of 
toxic reactive intermediates from metabolism in these cell types.  The specific 
CYP450 isoforms (i.e., CYP1A1, CYP1A2, and CYP1B1) that are responsible for 
the metabolism of B(a)P to the reactive BPDE metabolite are present in high 
abundance in several lung cell types [147], yet the exact histopathological events 
and mechanisms that take place in the lung after acute and early chronic B(a)P 
exposure are not completely known. In our pilot experimental dose studies (80 
mg/kg), we set out to determine what histopathological events in the lung may be 
contributing to B(a)P’s mechanism of pulmonary toxicity. In these preliminary 
pilot studies, we observed an increase in alveolar wall thickness, as well as an 
increase in the numbers of neutrophils and activated macrophages in rat lung 
tissue from 80 mg/kg dosed rats compared to normal untreated control rats. 
Thus, this dissertational research sought to provide insight into the biological and 
biochemical factors underlying B(a)P-mediated toxicity such as hyperplasia, 






Hyperplasia and hypertrophy in lung tissues 
 Hyperplasia and hypertrophy frequently occur together and may contribute 
to an increase in alveolar wall thickness.  Where hypertrophy is an increase in 
the size of the cell (which can be seen in the skeletal muscle during weight 
training), hyperplasia is an increase in the number of cells.  Hyperplasia can be a 
normal response (as seen in the glandular tissue of the breast during 
pregnancy), or an abnormal (atypical) response.  Atypical hyperplasia can be a 
preneoplastic response to a stimulus or secondary to a pathological cause. It has 
even been demonstrated to be a precursor in some cancers [148]. The cause of 
atypical hyperplasia may also be due to a chronic inflammatory response. 
 
Neutrophils and macrophages in the lung 
 
 An association between chronic inflammation and cancer has been 
recognized for a long time [149-151].   Experimental studies with rats, as well as 
molecular epidemiological studies in humans, have provided evidence that the 
influx of neutrophils into the airways is an important process that may link 
inflammation with carcinogenesis. Neutrophils (or polymorphonuclear 
neutrophils, PMNs) are the most abundant type of white blood cells, and are a 
critical part of the innate immune system.  Neutrophils can be identified in tissues 
by their unique nucleus which is divided into two to five lobes.  Neutrophils are 
normally found in the blood stream, but during the acute phase of inflammation 
they migrate from the vessels towards the site of tissue inflammation.  
Neutrophils have been demonstrated to increase during some environmental 





endothelium has been demonstrated to be related to an increase in endothelial 
injury [155, 156].  This damage is accomplished by the release of reactive 
oxygen and nitrogen species from an enzyme called myeloperoxidase (MPO). 
MPO enzymes are most abundant in neutrophils and are considered a 
marker of neutrophilic inflammation.  The reactive species produced by this 
enzyme are cytotoxic and intended to kill bacteria and pathogens.  However, 
MPO enzymes are nonselective in their targets, and therefore also induce 
cellular injury and necrosis in host tissue.  Neutrophil infiltration itself then 
becomes an offender in the pathogenesis of disease.  An association of MPO 
and the severity of coronary artery disease has been established [157].  
However, the role of MPO in lung injury and disease is still being ascertained.  
Like neutrophils, alveolar macrophages are white blood cells. Their role is 
to consume cellular debris and pathogens in the lungs to keep the lung’s 
environment sterile.  They also phagocytize neutrophils as they age [147]. They 
can stimulate lymphocytes and other immune cells, but unlike neutrophils, which 
are short-lived (about 2 days), macrophages can survive much longer in the body 
(up to several months) [158]. This may explain why the dominant inflammatory 
cells seen in chronic infections are macrophages [159]. Many agents that 
increase macrophage activity also increase the risk of inflammatory-related injury 
in the lung [160].  The disruption of the delicate balance of the macrophage 
population in the lung can have deleterious consequences [160].  Furthermore, 
macrophages have been demonstrated to promote cancer cell proliferation [161]. 





necrosis factor (TNF-α) release, which in turn activates nuclear factor-kappa B 
(NF-κB).  This arrests apoptosis and promotes cell proliferation and inflammation 
[162]. TNF-α release has also been demonstrated in a number of in vivo models 
of xenobiotic-induced lung injury [160]. 
Both the neutrophils and alveolar macrophages have been demonstrated 
to metabolize B(a)P, or B(a)P metabolites, to the ultimate carcinogen BPDE [163, 
164].  The resultant BPDE-protein and DNA adducts may contribute to the 
histopathological events in the lung after B(a)P exposure as well as mutagenesis.  
Figure 3.1 provides a simplified overview of the pathways by which these cells 
may impact pulmonary toxicology, and demonstrates the rationale behind our 
research objectives. 
 
Histopathology and staining techniques 
Histopathology is the study of microscopic anatomical changes that are 
characteristic of disease.  Since biological tissues have little inherent contrast 
using visible light microscopy, various staining techniques are employed to 
establish general relationships among cells in tissues.  Before biological tissues 
are processed for staining, chemical fixatives are used to preserve tissue from 
degradation.  The most common fixative for light microscopy is a 10% formalin  
solution. Permeation of tissues with this solution maintains the structure of the 
cell and sub-cellular components (mainly by irreversibly cross-linking proteins to  
formaldehyde), and prevents autolysis. The fixed tissue can then be sectioned 
and stained accordingly.  The hematoxylin and eosin (H&E) stain that was 










Figure 3.1  Simplified overview of the pathways by which neutrophils and 
macrophages may impact pulmonary toxicity. Neutrophils can cause not only 
oxidative DNA damage through generation of reactive species, but also are able 
to activate B(a)P metabolites to the ultimate carcinogen BPDE via metabolism by 
MPO [164-166]. Additionally, macrophages have been demonstrated to 
metabolize B(a)P to BPDE via P450-dependent and -independent pathways 











stains used today.  Hematoxylin is a basic dye that stains basophilic structures 
blue (i.e. nuclei and endoplasmic reticulum) and eosin is an acidic dye that stains 
eosinophilic structures pink (i.e., cytoplasm and red blood cells).  H&E staining 
therefore allows for the general study and differentiation of cell nuclei and 
cytoplasms in all types of tissues.   
Immunohistochemistry (IHC) exploits the principle of antibodies binding 
specifically to antigens (i.e., proteins) in biological tissues.  IHC is widely used in 
basic research to determine the localization and distribution of biomarkers in  
biological tissue. For the visualization of the antibody-antigen interaction, an 
antibody is conjugated to an enzyme.  A commonly used enzyme such as 
peroxidase can catalyze a color-producing reaction or the antibody can be 
tagged to a fluorophore which then could be detected under the appropriate 
fluorescent light.  
The experiments presented in this chapter were designed to address the 
hypothesis that the severity of lung tissue toxicity will correlate to the 
concentration of BPDE-protein adducts in hair. To determine the severity of lung 
tissue toxicity we:  1)  Measured  alveolar wall thickness and counted neutrophils  
in the lung tissue of control rats and B(a)P dosed rats by subjective means;  2)  
Measured nuclear space, cellular space, and air space by objective means;  3)  














Male Long-Evans rats (200-225 g) were individually housed in cages with 
wire mesh bottoms and maintained under controlled temperature and lighting 
conditions (12 hr light/dark cycle) and provided with food and water ad libitum. All 
procedures were in compliance with the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals [120].  
 
Chemicals and reagents 
B(a)P used for dosing solutions was purchased from Sigma-Aldrich®     
(St. Louis, MO). Containers with formalin solution (10%) for tissue fixation were 
obtained from ARUP laboratories (Salt Lake City, UT).  All other chemicals, 
reagents were obtained by the laboratories of ARUP Laboratories (Salt Lake 
City, UT) for H&E staining and IHC Services (Smithville, TX) for MPO staining. 
For ICH preparations the protein blocking solution was obtained from Signet 
Pathology Systems (Dedham, MA); The avidin /biotin blocking kit was purchased 
from Zymed Labs (San Francisco, CA);  SuperBlock was purchased from Pierce 
Chemical Company (Rockford, IL); Antibodies were obtained from SignetTM 
Laboratories (Dedham, MA) and New Fuchsin substrate from Kirkegaard & Perry  
Labs (Gaithersburg, MD). 
 
 
Experimental protocol and lung tissue collection 
 
 Two experimental groups were evaluated for evidence of the described  





Group 1:  Rats were administered 40 mg/kg of B(a)P (in corn oil) (n=10) i.p. once 
daily for 7 days.  Control rats (n=5) were dosed i.p. once daily with corn oil for 
seven days.  
Group 2:  Rats were administered 160 mg/kg of B(a)P (in corn oil) (n=10) i.p. 
once daily for 7 days. Saline control rats (n=5) were administered sterile saline 
solution i.p. once daily for 7 days.  Corn oil control rats (n=5) were dosed i.p. 
once daily with corn oil for 7 days. 
Solutions of B(a)P in corn oil were prepared at 25 and 100 mg/mL for the 
40 and 160 mg/kg doses, respectively. The volume of corn oil administered given 
i.p. to the corn oil control rats was based on the weight of the animal.  This was 
done in order to keep the dosed volume of corn oil consistent between all 
experimental groups.  The volume of saline was also based on the weight of the 
animal, therefore keeping the dosed volume equivalent to the other groups. For 
this study, the doses of B(a)P given are high and represent chronic lifetime doses 
of B(a)P in humans. In order to evaluate whether vehicle (corn oil) had any effect 
on inflammation or other events in the lung, an additional control group (saline 
dosed rats) was included with Group 2.   
Fourteen days after the first dose, the animals were anesthetized with  
chloral hydrate (450 mg/kg).  After hair and blood were collected (as described in 
Material and Methods section in Chapter 2), the animal’s diaphragm on each side 
was carefully pierced to allow the lungs to collapse. The lungs were then 
carefully extracted by the trachea, avoiding actual contact with the lung at all 





sectioning of tissue was performed.  The location of the nickel-thick section of 
lung tissue used for sectioning and staining for H&E and IHC can be seen in 
Figure 3.2. 
 
H&E staining of lung tissue 
 
 All of the H&E procedures were performed at ARUP laboratories (Salt 
Lake City, UT).  The nickel-thick gross section of lung tissue was allowed to 
equilibrate in 10% formalin overnight.  The next day, the tissue was paraffin 
embedded, then 3-5 micron paraffin sections were placed on positive charged 
slides and allowed to air dry at room temperature. Using an automated staining 
system (Tissue-Tek® PrismaTM), the slides were first deparaffinized in a 65°C 
drying oven then taken through a series of  xylene, alcohol, water, Harris 
hematoxylin, acetic acid, and eosin washes.  After the final rinsing and drying 
steps were complete, slides were transferred to an automated Tissue-Tek® 
FilmTM for coverslipping. 
 
Immunohistochemistry staining of lung tissue for MPO 
 
 All of the MPO staining procedures were performed at IHC Laboratories 
(Smithville, TX).  Five micron paraffin sections were placed on positive charged 
slides and allowed to air dry at room temperature.  The slides were then 
deparaffinized with ProPar® and hydrated down though a series of alcohols to  
covered with a protein blocking solution for 30 mins, and subsequently rinsed in 
Tris buffer.  An avidin/biotin blocking procedure was then performed, streptavidin-














Figure 3.2  Rat lung indicating the gross section of lung tissue used for paraffin 
embedding, sectioning, and H&E and immunohistochemistry staining.  The 












in water.  Slides were then placed into a 10 uM citrate buffer (pH 6.0) and heated 
in a microwave to boiling, then held at the boiling temperature for 6 mins. The 
slides were allowed to cool for 20 mins at room temperature.  Each tissue section 
was Slides were again rinsed in Tris buffer and New Fuchsin substrate applied.  
Color development was monitored microscopically, then slides were washed in 
distilled water and counterstained in Mayers’ hematoxylin. Slides then went 
through a brief rinse in an aqueous ammonia solution, then distilled water, then 
dehydrated though a series of alcohols.  Slides were dipped in ProPar®, then 
mounted. 
  
Subjective analysis of lung tissues 
 
An initial observation of the H&E stained lung tissue obtained from a pilot  
study in rats administered B(a)P (80 mg/kg, n=10) and  normal untreated rats  
(n=4) revealed that B(a)P appeared to cause alveolar wall thickening (possible 
hyperplasia or hypertrophy based), decreased air space, and an increase in 
neutrophils and activated macrophages.  Therefore, in our 40 mg/kg and 160 
mg/kg dosed rats groups, along with appropriate vehicle (corn oil) control rats 
and saline control rats, we subjectively measured the percentage of alveolar wall 
thickening and number of neutrophils evident in ten random 40X images taken 
around the pulmonary artery and main bronchus of each rat (analyst was blinded 
to treatment groups).   
The percentage of alveolar wall thickening was determined by observing 
the increase in the number of cells that made up the alveolar wall in ten 40X 





measurement, the exact number of neutrophils were recorded in 10 40X fields.  
The ten values obtained from each rat for percentage of alveolar wall thickening 
and neutrophil count were then averaged, yielding a mean value per rat. 
Statistical tests were then performed on these mean values between each of the 
groups tested.   Subjective measurements were done under the guidance of Dr. 
Lawrence McGill (a veterinarian and board certified veterinarian pathologist) at 
ARUP Laboratories.   
 
Objective analysis of lung tissue 
 
 ImageJ is a Java-based image processing program developed at the  
National Institutes of Health [168]. We employed this software as a second  
approach for assessing histopathological changes in lung tissues obtained from  
the control and B(a)P dosed rats.  Using this software, and digital images of the 
H&E stained lung tissue, we performed several densitometric measurements. 
First, the analyst was blinded to treatment group, then ten random fields 
(at 40X magnification) around the pulmonary artery and main bronchus were 
selected (examples shown in Figure 3.3).  Because densitometric measurements 
of cellular content were assessed, fields only containing alveolar epithelial cells 
were taken (to avoid offset of other lung parenchyma of differing cellular density). 
These images were all taken under the same camera and scope settings (i.e., 
exposure, contrast, etc.).  These images were then analyzed in Image J using 
pixel value statistics of user-defined selections of intensity thresholded objects. 
The threshold intensity was set for each measurement of interest, then held 










Figure 3.3  Representative digital images of H&E stained lung tissues.  
Whole lung (10X) (top) and alveolar cells (40X) (bottom).  Red circles 
around the pulmonary artery and main bronchus are representative areas 






measurements included:  1)  Cell Count (measure of hematoxylin stained nuclear  
space), Cellular Space (measure of eosin stained cytoplasmic material plus 
hematoxylin stained nuclear space), Air Space (measure of space not stained 
with hematoxylin or eosin), and ratios of these measures.  (Images of these 
measurements are represented above their respective data in the Results 
section.)  The “Cell Count” measurement may be representative of hyperplasia.  
“Cellular Space” may be representative of hypertrophy.  Decreased “Air Space” 
may be indicative of hyperplasia, hypertrophy, and/or inflammation.  A smaller 
than control value for the ratio of nuclear space to air space could be 
representative of hypertrophy. Whereas, a larger value than control value for the 
ratio of cellular space to air space could be indicative of hyperplasia, 
hypertrophy, and/or inflammation.  Figure 3.3 represents a whole lung slice 
showing representative areas where 40X images were obtained, and an example 





 Subjective measures of the percent of alveolar wall thickening and 
average neutrophil counts for the 40 mg/kg dosed rats and corresponding corn 
oil control rats were compared by a two-tailed Student’s t-test. Objective ImageJ 
results for Cell Count, Cellular Space, Air Space, and ratios were also compared 
by a two-tailed Student’s t-test between these two groups.  Subjective measures 
of the percent of alveolar wall thickening and average neutrophil counts for the 





were compared by a one-way ANOVA. Objective ImageJ results for Cell Count, 
Cellular Space, Air Space, and ratios between these groups were also compared 
by a one-way ANOVA.  All statistics were performed using Graph Pad Prism® 
software (version 5.01) (La Jolla, CA).  Differences were considered significant at 




 There was no statistical difference in the subjective measurement of 
alveolar wall thickening or average neutrophil counts between 40 mg/kg dosed 
rats and the corresponding corn oil control rats (Figure 3.4 A-B).  There was also 
no statistical difference in the subjective measurement of the alveolar wall 
thickening or average neutrophil count between 160 mg/kg dosed rats and the 
corresponding saline control and corn oil control rats (Figure 3.4 C-D). 
 The objective ImageJ measurements for Cell Count and Cellular Space 
can be seen in Figure 3.5.  There was no statistical difference between 40 mg/kg 
dosed rats and the corresponding corn oil controls for Cell Count or Cellular 
Space.  There was also no statistical difference between 160 mg/kg dosed rats 
and the corresponding saline control and corn oil control rats for Cell Count or 
Cellular Space (Figure 3.5).  
The objective ImageJ measurements for Air Space can be seen in Figure 
3.6.  There was no statistical difference between 40 mg/kg dosed rats and the 
corresponding corn oil controls for Air Space.  There was also no statistical  
difference between 160 mg/kg dosed rats and the corresponding saline control  























































































































































































































Figure 3.4  Subjective measurements (mean + SEM) for alveolar wall thickening 
and neutrophil counts for 40 and 160 mg/kg doses rats.  Panels A&B)  There is 
no statistical difference between alveolar wall thickening or neutrophil count for 
40 mg/kg dosed rats and corresponding corn oil control rats (P values for 
Student’s t-tests shown). Panels C&D)  There is no statistical difference between 
alveolar wall thickening or neutrophil count for 160 mg/kg dosed rats and 
































Figure 3.5  ImageJ results (mean + SEM) for Cell Count and Cellular Space.  
Thresholded area is shown in red above bar charts and corresponds to the 
percent area fraction shown on the y-axis. A&B)  Results for 40 mg/kg dosed rats 
and corresponding corn oil control rats. There is no statistical difference between 
40 mg/kg dosed rats and corresponding corn oil controls for Cell Count or 
Cellular Space. (P values for Student’s t-tests shown).  C&D)  Results for 160 
mg/kg dosed rats and corresponding saline and corn oil control rats. There is no 
statistical difference between 160 mg/kg dosed rats and corresponding saline 
control and corn oil control rats for Cell Count or Cellular Space. (P values for 

































Figure 3.6  ImageJ results (mean + SEM) for Air Space.  Thresholded area is 
shown in red above bar charts and corresponds to percent area fraction shown 
on the y-axis.  A)  Results for 40 mg/kg dosed rats and corresponding corn oil 
control rats. There is no statistical difference between 40 mg/kg dosed rats and 
corresponding corn oil controls for Air Space. (P values for Student’s t-tests 
shown).  B)  Results for 160 mg/kg dosed rats and corresponding saline control 
and corn oil control rats. There is no statistical difference between 160 mg/kg 
dosed rats and corresponding saline and corn oil controls for Air Space. (P 




















The measurements for the ratios of nuclear space to cellular space, and 
cellular space to air space, from ImageJ results can be seen in Figure 3.7.  There 
was no statistical difference between 40 mg/kg dosed rats and corresponding 
corn oil controls for either ratio. There was also no statistical difference between  
160 mg/kg dosed rats and corresponding saline and corn oil controls for either 
ratio.  
The results from MPO staining from 160 mg/kg dosed rats (n=3) and 
corresponding corn oil control rats (n=3) are shown in Figure 3.8.  There was a 
significant difference in the number of MPO stained cells between these two  
groups. The mean + SEM was 2.0 + 0.3 for the corn oil control rats 3.1 + 0.3 for  





 We determined that there is a significant difference in the IHC staining for 
MPO content between B(a)P dosed rats and control rats (Figure 3.8). However, 
we were unable to determine a statistically significant difference the lung tissues 
between B(a)P dosed rats and control rats using the described subjective and  
objective measures within this chapter.  This lack of significant difference may be 
due to several reasons:  1) There may be a lack of sensitivity in methods used for 
both subjective and objective measurements;  2) The lung tissues from animals 
were not insufflated at a constant pressure prior to collection; 3) The dosing 
paradigm included only one time point (Day14), seven days after the last B(a)P  
dose;  4)  The route of administration by i.p. may not be appropriate for short- 















Figure 3.7  Ratios of nuclear space to cellular space and cellular space to air 
space for ImageJ results (mean + SEM).  A&B)  Results for 40 mg/kg dosed rats 
and corresponding corn oil control rats. There is no statistical difference between 
40 mg/kg dosed rats and corresponding corn oil controls for either ratio. (P 
values for Student’s t-tests shown).  C&D)  Results for 160 mg/kg dosed rats and 
corresponding saline control and corn oil control rats. There is no statistical 
difference between 160 mg/kg dosed rats and corresponding saline and corn oil 
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Figure 3.8  Digital 100X image showing MPO stained cells (top) and results 
(mean + SEM) for MPO staining (bottom). There is a significant difference 
between the number of MPO stained cells between 160 mg/kg dosed rats and 








and residual nonuniform blood distribution in lung tissue may be contributing to 
discrepancies in the ImageJ measurements taken; 6) There are a multitude of 
cell types in the lung and we only performed measurements on one cell type 
(alveolar epithelial cells).  These topics will be expanded upon below. 
 
The use of deflated lung tissue 
 
Deflated lung tissue is commonly used to examine gross histopathological 
changes (i.e., hyperplasia, hypertrophy, metaplasia, neoplasia, necrosis, and 
tumors).  Insufflated lung tissues are commonly used for morphometric analyses 
of the numbers of bronchi, bronchioli and alveolar ducts, along with air space and 
space and pulmonary vascular bed measurements.  Additionally, using 
morphometric analyses, qualitative and quantitative measurements can be 
performed on lung tissues. We found that using deflated lung tissue resulted in 
inconsistent atelectasis (see top panel of Figure 3.9), which may have resulted in 
discrepancies in the densitometric measurements taken by ImageJ (i.e. higher 
cellular space percent area threshold values due to collapsed tissue and not 
because of an increase in cell numbers or size). 
 
Dosing paradigm 
 Recognizing that lung clearance and lung cell turnover is rapid, earlier 
time points for inflammatory responses may have resulted in a more pronounced 
difference between B(a)P dosed rats and control rats. However the current 
methods described in this chapter may still have not been sensitive enough to 





(several months to a year), metaplasia, neoplasia, and possible tumor formation 
is supported in rats dosed this high with B(a)P [71, 72, 169-171].   From H&E 
stained lung tissues from our pilot experiment (rats dosed at 80 mg/kg) and the 
40 mg/kg and 160 mg/kg dosed rats detailed in this chapter, we did observe 
increased in alveolar wall thickness, edema, and macrophage hyperplasia 
(representation shown in Figure 3.9 bottom panel).  We also noted there was 
decreased weight gain (from Day 0 to Day 14) in B(a)P dosed rats as 
compared to the control rats (Figure 3.10), which may also be contributing to the  
toxicity of B(a)P. 
 
Artifacts of H&E staining 
 
 Slight differences in the thickness of the lung tissue sectioned by a  
microtome cutting device can contribute to more, or less, H&E dye uptake.  This  
artifact of H&E staining may contribute to higher percent area thresholded 
measurement if the slice was thicker (thus more dye uptake), and conversely a 
trying to compare experimental groups.  The same microtome should be used for 
all samples, and the same technician should do all the paraffin blocked tissue 
sectioning.  Additionally, samples should all be processed together using the 
same batch of reagents and dyes.   
 
Cell type chosen 
 
 The lung contains over 40 different cell types and pneumotoxins are 
thought to only exert their toxic effects on six of these cell types.  Since it is  

















Figure 3.9  Images from H&E stained lung tissue showing: A) Atelectasis in 
tissue from Saline Control Rat. B)  Edema and macrophage hyperplasia in tissue 
from 160 mg/kg dosed rat.  A)  Yellow dashed line indicates one of the areas 
showing atelectasis.  B)  Red oval indicates an area of edema. Arrows indicate 
















































































































Figure 3.10  Results for weight gain/loss from Day 1 to Day 14. The average 
weight gain/loss for all B(a)P dosed rats were significantly different than the 
vehicle control (corn oil) rats (Student’s t-test, p<0.05).  Saline control rats are 










binding to proteins and DNA in the lung, as compared to hepatic cellular 
populations [147], this demonstrates the importance of the examination of 
ower percent area thresholded measurement if the slice was thinner (thus less 
dye uptake).  Also, different batches of H&E dyes could conceivably affect 
percent area thresholded measurements.  It is therefore important that protocols 
remain consistent between the lung tissues processed for H&E staining when  
specific cell types in the lung.  The heterogeneous distribution of drug-
metabolizing enzymes among lung cells [172] may greatly enhance the risk for 
cytotoxicity in certain cell types.  
 Clara cells have been demonstrated to be more susceptible to 
electrophilic intermediates (like the epoxide) than other lung cells [147], but the 
alveolar type II cells are considered to be at high risk for B(a)P-induced tumor 
formation [142].  A number of studies have also demonstrated that alveolar type 
II cells are important in the modulation inflammatory and immune events in the 
lung [173, 174].  These cells also have greater volume densities of mitochondria 
and endoplasmic reticulum than many of the other cell types, supporting that 
higher metabolic activities are present in these cells [175].  Unfortunately, the 
metabolic capacity of alveolar type I cell is unknown, due to the inability to isolate 
type I cells for in vitro studies. While there are greater numbers of alveolar type II 
cells, the alveolar type I cells covers >95% of the alveolar surface, and may mask 
effects in the less prominent alveolar type II cell population.  The alveolar 
epithelial cells, in general, are where we observed the most distinct gross 





(see images in Figure 3.11 and Figure 3.12).  The Clara cells however, contain 
the highest amounts of several CYP450 enzymes [147], and further examination 
of these cell types is warranted.   
 
Experiments not detailed in this chapter 
 The location around the pulmonary artery and main bronchus were 
chosen because we hypothesized that B(a)P given i.p. would be systemically  
introduced via the circulation, and thus the distribution of the resultant injury 
would be dependent on the pattern of blood flow to the lung.  While systemically 
introduced toxicant lung injury is thought to be quite uniform [175], the posterior 
sections of the lower lobes in rat lungs show increase toxicities with the PAH 
naphthalene [176].  We thus considered that different regions of the lung may 
have greater toxicities associated with B(a)P exposure based on blood pooling 
effects.  Based on this assumption, subjective and objective measurements 
described in this chapter, were performed on the posterior lobe and the anterior 
ventral portion of the lobe.  However, analysis of these distinct regions did not 
reveal a significant difference between B(a)P dosed animals and controls (data 
not shown). 
 In addition to evaluation of regional differences, Red O staining was 
employed to decipher whether the “spongy” appearance of macrophages in 
B(a)P dosed animals (Figure 3.9 bottom panel) was due to the presence of 
residual corn oil.  Red O staining indicates fat or lipids in fresh frozen tissue 









Figure 3.11  Representative H&E images of corn oil control rat lung (top panel) 







Figure 3.12  Representative H&E images of saline control rat lung(top panel), 
corn oil control rat lung (middle panel) and corresponding 160 mg/kg dosed rat 





abnormal places (e.g., tumors arising from fat cells (liposarcomas)). Tissues 
(n=3, corn oil controls; n=3, 40 mg/kg) from this experiment indicated the 
“spongy” appearance in macrophages was not due to the presence of corn oil, 
and B(a)P dosed animals and corn oil controls had similar staining patterns 
(which was very little to no stain present) (data not shown).  
 
Extrapolation from animal to human studies 
 There may be unique differences in the genetic variation and regulation of 
specific proteins within the lung that should be considered when comparing lung 
toxicities in rats and humans.  Spontaneous lung tumors in murine strains have 
been demonstrated to have similar histopathology and molecular characteristics 
to human adenocarcinomas [177, 178] .  However, only rudimentary respiratory 
bronchioles are present in rodent lungs, and the populations of cells in rats vs. 
humans are different, as well as cellular metabolism and cellular defense 
mechanisms [175].  There are also known differences in the sensitivity of alveolar 
macrophages to xenobiotics in murine strains [179]. While there has been a great 
deal of information obtained on xenobiotic induced lung injury, more important 
questions still remain to be answered. Particularly, it is important to determine if 
the human lung is more sensitive to B(a)P-induced toxicities than the rat lung.   
  
Future directions 
 Whole-genome microarrays in normal human epithelial cells exposed to 
BPDE show induction of numerous inflammatory factors [180].  These include 





prostaglandin synthesis and signaling.  In addition, Podechard et al. have 
demonstrated that interleukin-8 (a pro-inflammatory cytokine) induction by B(a)P 
is aryl hydrocarbon receptor-dependent and leads to lung inflammation and to 
increased oxidative stress [145].  With this, and numerous other data stemming 
from research on B(a)P-induced inflammation, biochemical markers for 
inflammatory pathways in the lung tissue is warranted. Flow cytometry for 
specific inflammatory markers and specific inflammatory cell types could provide 
much higher sensitivity than our described methods, and may be able to better 
determine whether measureable differences are present in lung tissues from 
B(a)P dosed rats and control rats.  
 Experiments could be repeated with insulflated lung tissue and then 
morphometric measurements (or quantitative morphology) could be performed.  
Morphological abnormalities are the most reliable evidence we have to date for 
alveolar epithelial cells, since there are a lack of epithelial specific biochemical 
markers [175].   
 Electron photomicroscopy could provide better resolution of the cell types 
in lung tissue in order to examine any epithelial injuries or abnormalities in cell 
structure. Potential increases in the number of cells undergoing DNA synthesis 
can also be evaluated by this type of microscopy.  
Cellular necrosis can contribute to an increase in alveolar protein 
concentrations.  Injured cells release soluble enzymes from the cell’s cytosol into 
extracellular fluids.  These soluble enzymes can then be measured and used as 





Very few studies have examined BPDE-protein adduct formation and 
specific tissue toxicities [181, 182].  The experiments detailed in this chapter 
aimed to understand whether or not B(a)P and/or BPDE-protein adduct 
concentrations in hair can serve as biomarkers, not only of exposure to B(a)P, 
but also as a predictor of increased lung toxicities.  Further research will be 
needed to elucidate if the presence of BPDE-protein adducts in biological 
matrices such as hair and specific lung toxicities are associated. 
 In conclusion, despite more than 80 years since B(a)P has been isolated, 
much still remains to be learned about the underlying mechanisms that contribute 
to B(a)P-induced lung toxicity.  A better understanding of the biochemical events 
that surround these toxicities would help us better recognize the relationship 
between functional alterations and structural changes in the lung.  The cellular 
fate of metabolic and inflammatory induced injury after B(a)P exposure are 



















BIOMARKERS OF BENZO(A)PYRENE EXPOSURE IN THE HAIR AND  
 






Smoking causes about 440,000 deaths and generates an estimated $157 
billion in health-related economic losses in the United States annually [183].  
Lung cancer is the leading cause of cancer death in the United States and is the 
most common type of tumor worldwide [184]. Since tobacco smoking is the 
single most important risk factor for development of lung cancer, it is strongly 
implicated as the causative agent [184].  It is also well established that active 
tobacco smoking can cause cardiovascular diseases, respiratory illnesses and 
other serious and often fatal health conditions.  Moreover, evidence is rapidly 
accumulating that both platelet and endothelial function, arterial stiffness, 
atherosclerosis, oxidative stress, inflammation, heart rate variability, energy 
metabolism, and increased infarct size are seen not only in the active smoker, 
but also in nonsmokers exposed to environmental tobacco smoke (ETS) [185].  
Although several studies have demonstrated the usefulness of biomarkers, such 
as cotinine, for ETS and particulate tobacco smoke (PTS) exposure, these 





Therefore, more studies are needed to develop new and enhanced biomarkers 
that will address tobacco smoke exposure and the toxicity risks associated with 
smoking and exposure to ETS. Advantages of improved biomarkers include: 1) 
They can be used in epidemiological and health surveillance programs as well as 
new product and harm-reduction studies. 2) They can improve quantitative risk 
assessments and exposure reduction studies for tobacco smoke exposures. 3) 
They can provide a tool for assessing individual exposure for smoking 
intervention programs and chemoprevention studies. 4) They can provide data 
for studies regarding smoking cessation in special populations such as 
adolescents, pregnant women, or medical patients with smoking-related 
diseases. 5) They can be used to evaluate and improve upon the accuracy of 
self-reported status smoking in observational studies, as well as expand our 
knowledge on the utility of hair biomarkers for determining ETS and PTS 
exposures.  
The Environmental Protection Agency (EPA) estimates that the exposure 
to B(a)P is 1-3 ug/day for nonsmokers [76].  It has been determined that the 
predominant pathways of exposure to B(a)P for nonsmokers is through inhalation 
of polluted air and ingestion of food containing B(a)P [186]. The major route of 
exposure for smokers, however is through inhalation of PTS and ETS [186]. The 
amount of B(a)P exposure in smokers can vary widely, but has been 
approximated at 1-30 ug/pack/day [63, 82-85].  Polycyclic aromatic hydrocarbons 
(PAHs) have also been demonstrated to be 3-4 times higher in ETS [187], so 





it is considered a minor route of exposure, B(a)P can also be absorbed through 
the skin [188].  
The metabolic activation and detoxification of B(a)P varies widely among  
humans and a large interindividual variation has been noted [73, 127, 189-193]. 
Higher metabolic activity to form the reactive metabolite BPDE, or lower 
detoxification of BPDE, would presumably be associated with a higher risk of 
cancer. Measurement of biomarkers that can reflect this higher cancer risk would 
be of great importance.  Using a biomarker in a surrogate tissue such as hair, 
whose collection is noninvasive and which serves as a marker for cumulative 
exposures, would have major advantages over tradition matrices. Additionally, 
hair biomarkers for nicotine and cotinine have been demonstrated to identify 
exposure for up to 10 weeks posttobacco use, thus providing a larger window of 
detection and a more accurate account of tobacco smoke exposure [194].  
 Protein adducts can serve as a measure of internal dose of a carcinogen. 
While DNA is the target in carcinogenesis, BPDE-DNA adducts levels are 
generally too low to detect in blood [60]. For this reason, protein adducts are 
employed as surrogates for DNA adducts because of their greater availability 
from blood.  Additionally, BPDE-protein adduct levels have been demonstrated to 
reflect genetic damage, and have a strong degree of correlation with BPDE-DNA 
adducts [60, 98, 127].  Previous methods have used BPDE adducts to Hb and 
serum albumin as surrogates for BPDE-DNA adducts [60, 98, 127]. These 
protein adducts are much easier to collect in large quantities, compared to DNA 





obtain lung tissue from human subjects, the ability to establish a relationship 
between B(a)P and/or BPDE-protein adducts in hair to that found in the lung, 
would be an invaluable tool for assessing toxic ETS and PTS exposures. 
The experiments presented in this chapter were designed to address the 
following objectives:  1) Develop sensitive and specific GC/MS analytical 
methods to detect B(a)P and BPDE-protein adducts in human hair;  2)  
Determine the differences of B(a)P incorporation in smokers (those exposed to 
PTS) and nonsmokers (those with no exposure to PTS or ETS) hair;  3) 
Determine the differences in BPDE-protein adducts in the hair and Hb (from 
blood)  of smokers and nonsmokers; 3) Determine if the concentration of B(a)P 
and/or BPDE-protein adducts in hair correlate to the concentration of the well 
characterized BPDE-Hb adduct (the positive control);  4) Verify self-reported 
status of smokers and nonsmokers by determining nicotine and cotinine 
concentrations in plasma.  We hypothesized that we will be able to detect a 
significant difference in the concentration of B(a)P and BPDE-protein adducts 
measured in hair from heavy smokers vs. nonsmokers.   
 
Materials and Methods 
 
 
Chemicals and reagents 
 
 Benzo(a)pyrene (1 mg/mL) was purchased from SPEX Certiprep®, Inc. 
(Metuchen, NJ), Restek (Austin, TX ), and AccuStandards® (2 mg/mL) ( New 
Haven, CT) for the preparation of calibration curves and quality control samples. 





Certiprep®, Inc. (Metuchen, NJ). BPT (5 mg) was purchased from the National 
Cancer Institutes Chemical Repository (Midwest Research Institute, Kansas City, 
MO). The internal standard [13C6]-BPT (1 mg), was purchased from Cambridge 
Isotopes Laboratories, Inc. (Andover, MA) by Dr. Stephen Hecht of Masonic 
Cancer Center (University of Minnesota), and generous gift of a 1200 ng/mL 
[13C6]-BPT solution (1mL in DMSO) was provided for this dissertational research.  
(−)-Nicotine hydrogen tartrate salt was obtained from Sigma-Aldrich® (St Louis, 
MO). (−)-Cotinine, (±)-cotinine-d3 and (±)-nicotine-d3 were obtained from 
Cerilliant (Austin, TX). Hexane, dichloromethane (DCM), methanol, acetonitrile, 
ethyl acetate were all GC/MS or high performance liquid chromatography grade 
and purchased from Burdick & Jackson
®
 (Morristown, NJ & Muskegon, MI).  
Acetone (GC/MS grade) was purchased from EMD (Gibbstown, NJ), and 
anhydrous tetrahydrofuran (THF) was purchased from Sigma-Aldrich® 
(Milwaukee, WI). Ammonium acetate and glacial acetic acid were obtained from 
Spectrum (Gardena, CA). Proteinase K (from Tritirachium album, activity >30 
units/mg) was purchased from Sigma-Aldrich®. The derivatization agent (N-
Methyl-N-(trimethylsilyl) trifluoro-acetamide activated II, MSFTA II) was 
purchased from Fluka (Castle Hill, New South Wales, Australia), Sep-Pak® C18, 
3cc solid phase extraction (SPE) cartridges were purchased from Waters 
Corporation (Milford, Massachusetts).  Oasis
® 
HLB and MCX (60 mg, 3mL) 
cartridges were purchased from Waters (Milford, MA).  Trichloroacetic acid, 
concentrated formic acid, concentrated ammonium hydroxide, and all other 





Sigma-Aldrich® and Fluka.  Water used was house-prepared Milli-Q water. 
Helium and ammonia gases used for GC/MS analysis were purchased from 
Airgas, Inc.
 ®
 (Salt Lake City, UT). Lyophilized human hemoglobin was obtained 
from Sigma-Aldrich®.  RBC lysis buffer was purchased from Roche (Branford, 
CT) and phosphate buffered saline solution from Teknova (Hollister, CA). Sodium 
heparin Vacutainers® were purchased from BD (Franklin Lakes, NJ).  Nicotine- 
and cotinine-free human plasma was obtained from BioChemed (Winchester, 
Virginia, USA).  Hair collection kits were obtained from AgriYork (York, England). 
 
Stocks and solutions 
 
Intermediate stock solutions of B(a)P and B(a)P-d12 were prepared in 1:1 
acetone/DCM at a concentration of 5000 and 500 ng/mL. Intermediate stock 
solutions of BPT were prepared in fresh anhydrous THF at a concentration of 
5000 and 100 ng/mL.  Intermediate stock solutions of [13C6]-BPT were prepared 
in fresh anhydrous THF at a concentration of 100 ng/mL.  Since B(a)P and BPT 
are light and air sensitive, all solutions were made in amber vials with septum 
screw caps to avoid over exposure to light and air and stored at -20°C in air-tight 
jars.  Matrix-fortified calibration curves and quality control samples were prepared 
daily. The quality control samples for B(a)P that were prepared with each batch 
of samples, and for determination of assay imprecision and accuracy, were 
fortified with a reference material from a different manufacturer than that used to 
prepare the calibration curve for B(a)P.  Since no other commercial source was 
available for BPT, a separate stock and intermediate solution for the quality  





  For nicotine and cotinine assays, the deuterated internal standards were 
prepared in a single combined working solution in methanol at 1 μg/mL. This 
solution was stored in the freezer at -20°C until required for an analytical batch. 
For nicotine and cotinine, three combined calibrator working solutions were 
prepared in methanol at concentrations of 10 μg/mL,1 μg/mL and 0.1 μg/mL for 
nicotine and cotinine. Nicotine hydrogen tartrate salt (weight corrected for 
nicotine) was selected as it was determined to be more stable over time than 
nicotine free base. Separate methanolic working solutions were prepared for 
quality control samples at the same concentrations as the calibrator working 
solutions. All working solutions were stored in the freezer at −20 °C until required 
for an analytical batch. 
 
Human clinical trial participants 
 
To optimize the potential for detecting of B(a)P and/or BPDE-protein 
adducts (assuming incorporation may be dependent upon melanin content), only 
dark pigmented hair samples were obtained from subjects enrolled in human 
clinical trials approved by the Institutional Review Board at the University of Utah 
and the University at Buffalo, SUNY (Buffalo, NY).  The study participants were 
subdivided into two groups.  Group 1 consisted of male and female nonsmoking 
participants, and Group 2 consisted of male and female heavy-smoking 
participants (defined as smoking at least one pack of cigarettes per day).  
Group 1 participants (nonsmokers) were screened by telephone using a 
questionnaire to exclude participants with potentially higher levels of 





Questionnaire). Any subject with higher than normal consumption of smoked or 
charbroiled foods were excluded, along with any subject with known occupational 
exposure to B(a)P. Hair samples from nonsmoking participants meeting inclusion 
criteria (n=20) were collected by personnel from the Center for Human 
Toxicology at the Center for Clinical and Translational Science at the University 
of Utah Hospital.  A “pencil-width” amount of hair (about 90-120 strands) was cut 
as close to the scalp as possible from each participant in the posterior vertex 
region of the scalp (see Figure 4.1).  Hair samples were then placed in a hair 
collection kit to mark the root end, and stored in the dark at 4°C in a Ziploc® bag 
until further sample preparation.  
Fresh whole blood was also obtained from the Group 1 participants by 
venipuncture at the Center for Clinical and Translational Science (University of 
Utah Hospitals, Salt Lake City, UT).  All blood samples were collected in sodium 
heparin BD Vacutainers®.  Whole blood samples were then centrifuged at 3000 
rpm for 10 mins to separate plasma from red blood cells (RBCs).  The plasma 
portion (collected for determination of nicotine and cotinine levels on all 
participants to verify nonsmoking status) was transferred to silanized glass 
culture tubes and stored at -20°C until preparation for nicotine and cotinine 
analysis.  The RBC portion remaining in the Vacutainer® was stored at 4°C until 
Hb preparaton. 
 Group 2 participants (heavy smokers), were screened by telephone  
by Dr. Stephen Tiffany’s laboratory at the University at Buffalo, SUNY (Buffalo, 











Figure 4.1  Drawing illustrating the posterior vertex region where hair was 
collected. (Adapted from [195].)  Hair samples are collected from this region 
since approximately 85% of hairs in this region are in the active growth phase 











(using questions 7-9 on Screening Questionnaire, see Appendix), and collected  
cigarettes) per day.  A “pencil-width” amount of hair (about 90-120 strands) was 
cut as close to the scalp as possible from each participant in the posterior vertex 
region of the scalp, then placed in a hair collection kit to mark the root end and 
shipped to the Center for Human Toxicology.  Upon arrival, hair collection kits 
were placed placed in Ziploc® bags and stored in the dark at 4°C until sample 
preparation.              
 Fresh whole blood was also obtained from the Group 2 participants by 
venipuncture by a registered nurse employed by the University at Buffalo, SUNY 
 (Buffalo, New York).  All blood samples were collected in sodium heparin BD 
Vacutainers®.  Whole blood samples were then centrifuged at 3000 rpm for 10 
mins to separate plasma from red blood cells (RBCs).  The plasma portion 
(collected for determination of nicotine and cotinine concentrations on all 
participants to verify self-reported current smoking status) was transferred to 
silanized glass culture tubes and stored at -20°C until shipped to the Center for 
Human Toxicology.  The RBC portion remaining in the Vacutainer® was stored at 
4°C until shipped.  Plasma and RBCs were kept cold during transport with ice 
packs.  Plasma samples were then stored at -20°C until preparation for nicotine 





B(a)P:  Hair preparation and extraction 
 





each sample, then homogenized by cutting into 2-3 mm segments.  Hair (100 
mg, +10%) was then accurately weighed (Mettler Toledo, AG104). The hair 
samples analyzed therefore represent approximately the last 3 months of 
exposure based on an assumption of an average 1 cm/month growth rate [11].  
B(a)P-d12 internal standard (IS) (100 pg/mg) was then added to each sample. 
Calibrators (10-100 pg/mg) and QC’s (45, 60, 80 pg/mg) were concurrently 
prepared by fortification of B(a)P and IS to analyte-free (blank) human hair.  After 
digestion of the hair in 1.0 mL of 1 N sodium hydroxide for 1 hr in a shaker, a 
0.100 mL aliquot of concentrated hydrochloric acid was added to neutralize the 
sample.  Samples were then centrifuged at 3500 rpm for 4 mins and 
subsequently subjected to solid phase extraction (SPE). The SPE was performed 
as follows:  2.5 mL of methanol followed by 2.5 mL of Milli-Q water was used to 
condition the column.  The liquid portion from the centrifuged hair sample was 
then decanted into the SPE cartridge (to improve complete transfer, 1 mL of Mill-
Q water was added to each hair sample, centrifuged again at the specified 
conditions, and the liquid portion decanted into the SPE cartridge). The columns 
were then washed with 2.5 mL of water followed by 2.5 mL of 10% aqueous 
methanol (v/v).  Samples were eluted by the addition of two volumes of 2.5 mL 
1:1 acetone/ dichlormethane. Eluents from samples were dried under a constant 
stream of nitrogen in a Zymark Turbovap® LV evaporator at 55°C.  Residues 
were then reconstituted in 0.100 mL of 1:1 acetone/ dichloromethane and 









BPT:  Hair preparation and extraction 
 
Multiple digestion and extraction methods were initially evaluated in order 
to detect BPT and IS fortified to analyte-free human hair.  First, the enzymatic 
extraction method for the release of BPT from BPDE-protein adducts in rat hair, 
which we previously validated (Chapter 2, Materials and Methods section), was 
evaluated for use with human hair.  Preparation and extraction were as follows:  
Analyte-free (blank) human hair (100 mg (+10%)) was weighed (Mettler Toledo, 
AG104) and BPT and  [13C6]-BPT IS (100 pg/mL) were added. To each hair 
sample, 2 mL of  200 ug/mL Proteinase K in incubation buffer (50 mM Tris buffer, 
5 mM calcium chloride, pH 8.5) was added to liberate any bound analyte from 
hair shaft constituents.  Samples were then placed in a sonicator for 1 hr (~37°C) 
and then transferred to a 37°C water bath and allowed to incubate overnight 
(total time ~20 hrs). After cooling, approximately 0.25 g of sodium chloride (NaCl) 
was added to each sample. A liquid-liquid extraction was then performed. Ethyl 
acetate (6 mL) was added to each hair digestion solution, which was then 
thoroughly vortex mixed followed by centrifugation at 3500 rpm for 4 mins. The 
liquid-liquid extraction was performed twice, and then the combined organic 
fractions were placed in a Zymark Turbovap® LV evaporator at 55°C under a 
constant stream of N2 until dry. The residues were then derivatized by adding 50 
uL of MSTFA and allowing for 15 mins reaction time in a heating block at 80°C. 





GC/MS-NCI-SIM (see GC/MS-NCI-SIM analysis for BPT section for additional 
details). 
 In addition to the enzymatic digestion and extraction procedure outlined 
above, numerous other analytical digestions and extraction techniques were 
evaluated.  These included:  acidic (using varying concentrations of hydrochloric 
and sulfuric acid solutions), alkaline (using varying concentrations of sodium 
hydroxide and sodium sulfide solutions), and solvent digestions (using methanol) 
of BPT (and IS) fortified human hair samples. These hair sample digests were 
then coupled to either liquid-liquid (using hexane or ethyl acetate) and/or SPE 
(using various types of SPE cartridges) extraction techniques. 
 
BPT:  Hemoglobin preparation from whole blood and extraction 
 
The RBCs from whole blood were isolated using a modified procedure 
from Ragin et al. [93].  Upon arrival of Group 1 and/or Group 2 samples to the 
laboratory, the RBC portion from whole blood was washed twice with equivalent 
volumes of 0.9% sodium chloride solution in Milli-Q water to remove any free, 
unbound BPT (from metabolism by epoxide hydrolase or reaction with water). 
One volume of phosphate buffered saline (PBS) was then added, and two 
volumes of RBC lysis buffer to re-suspend the RBCs (e.g., 3 mL RBCs then 3 mL 
of PBS and 6 mL of RBC lysis buffer). This was done to keep volumes of 
reagents used consistent between samples of differing volumes.  The samples 
were then gently shaken for 10 mins for lysis of RBCs, followed by centrifugation 
at 2000 rpm to pellet ghost membranes. The supernatant was removed from 





acid) was slowly added dropwise to precipitate Hb.  After 5 mins, the samples 
were centrifuged to pellet the precipitated Hb, and the excess fluid was decanted.  
The Hb pellet was then taken to dryness in a Zymark Turbovap® LV evaporator 
under a constant stream of nitrogen at 37°C and stored at -80°C until preparation 
for analysis. A 200 mg (+ 10%) aliquot of Hb (prepared as described above) was 
weighed (Mettler Toledo, AG104) and IS (10 pg/mg) added. Calibrators (1.75-10 
pg/mg) were concurrently prepared by fortification of BPT and IS to analyte-free 
(blank) human Hb. Two milliliters of NANOpureTM water and 30 uL of 6 N 
hydrochloric acid were added to each Hb sample, tightly capped, and placed in a 
water bath for 3 hrs at 90°C. Samples were allowed to cool, then approximately 
0.25 g of sodium chloride was added to each sample. A liquid-liquid extraction 
was then performed.  Ethyl acetate (6 mL) was added to each Hb hydrosylate, 
then thoroughly vortex-mixed, and centrifuged at 3500 rpm for 4 mins. The liquid-
liquid extraction was performed twice, and the combined organic fractions were 
placed in a Zymark Turbovap® LV evaporator @ 52°C under a constant stream of 
N2 until dry.  MSTFA (50 uL) was added to the residues and a 15 min reaction 
time was allowed in a hot block at 80°C. Samples were then transferred to 
autosampler vials for analysis by GC/MS-NCI-SIM (see GC/MS-NCI-SIM 
analysis for BPT section for additional details).  
 
Nicotine and cotinine:  Plasma preparation and extraction 
 
Plasma samples for participants were analyzed according to the 
laboratory’s validated published method [196].  One mL of each participant’s 





50 ng/mL for nicotine and 1-100 ng/mL for cotinine) and QC’s (5, 25, 45 ng/mL 
for nicotine; 1, 10, 100 ng/mL for cotinine) were concurrently prepared by 
fortification of nicotine and cotinine plus respective internal standards to 1 mL of 
analyte-free plasma.  To aid in matrix clean-up, 1 mL of 10 % aqueous 
trichloroacetic acid was added to each of the plasma samples, vortexed, and 
then centrifuged for 10 mins at 1100x g. The acidified plasma supernatant was 
then subjected to SPE using a combination of Oasis® HLB and Oasis® MCX 
mixed mode cartridges. The SPE cartridges were conditioned with 2 mL 
methanol followed by 2 mL 10% aqueous trichloroacetic acid. The samples were 
loaded onto the cartridges and subsequently eluted with 2 mL methanol 
containing 5% concentrated aqueous ammonium hydroxide (v/v). One hundred 
μL of 1% concentrated aqueous hydrochloric acid in methanol (v/v) were then 
added prior to evaporation of the eluant. Extracts were evaporated to dryness 
under a stream of air at 40 °C using a Zymark Turbovap® LV evaporator. 
Extracted plasma residues were reconstituted in 150 μL of initial mobile phase 
(10 mM ammonium acetate with 0.001 % formic acid (A) (pH 5): methanol (B) 
(85:15 v/v)).  (See LC-MS/MS analysis of nicotine and cotinine section for 
additional details). 
 
GC/MS-EI-SIM analysis for B(a)P 
 
A Hewlett Packard (HP) GC 6890 was fitted with an Agilent DB-5UI-MS 
capillary column (part no. 122-5535UI, 30.0 m x 250 um x 0.25 um nominal). The 
injector was operated in the pulsed splitless mode (injection pulse 40 psi until 0.2 





was programmed to 17.0 psi (total flow 33.8 mL/min). The inlet heater 
temperature was set at 300°C and the transfer line was set at 300°C.  The 
injection volume was 1 uL. The solvent delay was set at 7 mins. The initial oven 
temperature was set at 120°C for 1 min, then ramped to 250°C at 25°C/min A 2nd 
ramp to 320°C at 10°C /min followed, then oven was held at 320°C for 0.5 mins. 
The total run time equaled 16.7 mins. An HP MS 5973 was used to perform 
selective ion monitoring (SIM) to detect B(a)P at m/z 252 and its fragment at m/z 
126. B(a)P-d12 was detected at m/z 264. To quantitate the results, ChemStation 
software (version: D.02.00.275) was used to generate calibration curves from 
peak area ratios of target analyte to the corresponding deuterated internal 
standard across the concentration range of specified calibrators.  
 
GC/MS-NCI-SIM analysis for BPT 
 
The same GC/MS system and column was used as stated in the GC/MS-
EI-SIM analysis. The injector was operated in the pulsed splitless mode (injection 
pulse 17.6 psi until 1.33 min, purge flow to split vent 30 mL/min at 1.75 min). The 
pressure of helium gas was programmed to 24.3 psi (flow 2.2 mL/min, total flow 
34.5 mL/min).  Ammonia reagent gas pressure was set at 17.0 mL/min The inlet 
heater temperature was set at 280°C.  The transfer line was set at 300°C.  The 
injection volume was 2 uL and the solvent delay was set at 9.0 mins. The initial 
oven temperature was set at 120°C for 1 min, then ramped to 250°C at 20°C/min 
A 2nd ramp to 300°C at 8°C /min followed. The total run time equaled 13.75 mins. 
SIM was used to detect the derivatized BPT molecule at m/z 446 (no other 





was detected at m/z 452. To quantitate the results, ChemStation software 
(version: D.02.00.275) was used to generate calibration curves from peak area 
ratios of target analyte to the corresponding deuterated internal standard across 
the concentration range of specified calibrators. 
 
LC-MS/MS analysis of nicotine and cotinine 
 
An Acquity UPLC® system (Waters®, Milford, MA ) and  a Discovery® HS 
F5 HPLC column (100 mm × 4.6 mm, 3 μm, Supelco®, Bellefonte, PA) was used 
for analysis of nicotine and cotinine to verify nonsmoking and heavy smoking 
self-reported status of participants.  A gradient consisting of 10 mM ammonium 
acetate with 0.001 % formic acid (pH 4.97) (A), and methanol (B) was used at a 
flow rate of 0.6 mL/min The initial mobile phase condition was 15% B which was 
increased linearly to 76 % after 11 mins, then decreased back to the initial mobile 
phase condition of 15 % B after 11.6 mins and held for 3.4 mins to re-equilibrate 
the LC column.  The mass spectrometer was operated in positive ion 
electrospray mode using multiple reaction monitoring (MRM) data acquisition. 
Two MRM transitions were monitored for both nicotine (163.2 → 130.0 and 163.2 
→116.9) and cotinine (177.2 → 79.9 and 177.2→  97.9). The following ESI 
conditions were applied: capillary voltage 3.25 kV; source temperature 100°C; 
desolvation temperature 350°C; desolvation gas (nitrogen) 600 L/h; cone gas 
(nitrogen) 50 L/h; collision cell pressure (argon) 7.38e−3 mbar; and collision gas 
flow rate 0.35 mL/min  Mass spectrometric analysis was performed using a 
Quattro Premier XE™ triple quadrupole mass spectrometer (Waters® 





generated from peak area ratios of target analyte quantification ions to their 
corresponding deuterated internal standard quantification ions, across the 
concentration ranges of the calibrators. The calibration graphs were generated 
using the TargetLynx™ feature of the MassLynx™ v 1.4 software and also using 





Analytical method for B(a)P in human hair 
 
 We originally planned to validate a quantitative method for detection of 
B(a)P in human hair with a sensitivity at or below 1 pg/mg.  However we were 
unable to achieve adequate reproducibility (CV<20%) at concentrations below 20 
pg/mg; therefore, the following qualitative method was developed. 
 Figure 4.2 shows representative ion chromatograms for an extracted 
B(a)P-fortified (75 pg/mg) human hair and an extracted blank human hair 
sample.  The assay was determined to be linear from 20 to 100 pg/mg. The limit  
concentration of analyte at which the qualifying secondary ion was present and 
the chromatograms for ions of interest showed Gaussian peak shape with S/N 
ratio > 3.  
 Samples for determination of assay accuracy and imprecision were 
prepared with a stock solution purchased from a different manufacturer from that 
used to make the calibration curve standards. The intraassay accuracy and 
imprecision of the method were determined by analyzing  replicate samples of 



















Figure 4.2 Representative ion chromatograms from (A) extracted analyte-free 
(blank) human hair sample and (B) an extracted B(a)P-fortified (75 pg/mg) 
human hair sample.  Analyte retention time (RT) is on the x-axis and signal 
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mean observed concentrations of samples tested is an estimated of imprecision.  
The percent CV was calculated by dividing the standard deviation of the samples 
tested by the mean observed concentration of the samples.  This value was then 
of detection (LOD) was 20 pg/mg. The LOD was defined as the lowest  
multiplied by 100 to obtain a percentage.  Acceptable accuracy (% difference 
compared to target concentration within ± 20 %) and imprecision (%CV<20)  
for low, medium and high concentrations of B(a)P-fortified human hair were  
demonstrated within an analytical batch (Table 4.1). 
 
Analytical Method for BPT in Human Hair 
 
 Figure 4.3 shows representative chromatograms from an extracted 10  
pg/mg BPT-fortified 100 mg human hair sample (same preparation and extraction  
as described in Chapter 2 for rat hair).  The chromatographic peaks indicated for  
BPT and IS in this figure illustrate the significantly reduced sensitivity and 
recovery of BPT in fortified human hair, as compared to that observed for rat hair 
(refer to Figure 2.6 in Chapter 2 for 5 pg/mg BPT-fortified rat hair 
chromatograms). The IS response is approximately 95% lower than what was 
observed for rat hair matrix. Therefore, the digestion and extraction procedure 
that was used for the rat hair was determined to be inadequate for determination 
of BPT in human hair. 
 Several other digestions and extractions of BPT and IS fortified human 
hair samples were attempted.  The details for these digestions and extractions 
are shown in Table 4.2.  For most digested and extracted samples, we were 






Accuracy and imprecision of B(a)P-fortified human hair 
 





Concentration % of Target %CVb 
  pg/mg   pg/mg     
Intraassay 
     
 
45.0 3* 40.9 90.8 2.9 
 
60.0 3* 63.2 105.3 12.6 
 
80.0  4 82.7 103.4 16.6 





Concentration % of Target %CVb 
  pg/mg   pg/mg     
LOD 
     
 
20.0 4 23.1 115.7 6.0 
      ULOD 
     
 




    
 
a Number of quality control replicate samples used 
b CV= coefficient of variation 


















Figure 4.3 Ion chromatograms from an extracted BPT-fortified (10 pg/mg) human 
hair sample.  These chromatograms illustrate the reduced sensitivity for the 
detection of BPT in human hair (refer to Figure 2.6 in Chapter 2 for 5 pg/mg BPT-
fortified rat hair ion chromatograms).  Analyte retention time (RT) is on the x-axis 
and signal intensity on the y-axis. B(a)P = 252 m/z and B(a)P-d12 264 m/z 
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BPT-fortified human hair digestions and extractions 
     
  
Concentratio






























5 100 1 mL of 2.5 M NaOH 
and sonication for 2 hrs 
Liquid-liquid with 
hexane* 
ND [59] # 
5 100 1 mL of 1 N NaOH and 
sonication for 1 hr 
Liquid-liquid with 
ethyl acetate* 
ND n/a # 
5 100 1 mL of 2.5 M NaOH 
and sonication for 2 hrs 
SPE with Oasis® 
MAX cartridge* 
ND [197] # 




ND [198] # 




ND [198] # 
10 100 1 mL proteinase K 
solution, 1 hr sonication, 
and over-night 
incubation at 37C 
Liquid-liquid with 
ethyl acetate 
ND [199] # 
10 200 1 mL proteinase K 
solution, 1 hr sonication, 




ND [199] # 
80 100 1 mL proteinase K 
solution, 1 hr sonication, 
and overnight incubation 
at 37°C 
SPE with C18 
cartridge 
<10% [199] # 




ND [198] # 
80 100 2 mL of 1 N HCl 
overnight digestion at 
room temperature 
SPE with  C18 
cartridge 
ND [109] # 
100 100 30 uLof 6 N H2SO4, 3 
hrs incubation at 90°C 
Liquid-liquid with 
ethyl acetate 
followed by SPE 
with C18 cartridge 
ND [93] **
* 
100 100 60 uL of 6 N H2SO4, 3 
hrs incubation at 90°C 
Liquid-liquid with 
ethyl acetate 
followed by SPE 
with C18 cartridge 
ND [93] **
* 
100 100 120 uL of 6 N H2SO4, 3 
hrs incubation at 90°C 
Liquid-liquid with 
ethyl acetate 
followed by SPE 
with C18 cartridge 
ND [93] **
* 
100 100 Sonication in 3 mL of 
methanol 
n/a ND [109] # 
ND – not detected; * Sample was neutralized with hydrochloric acid before extraction; 







in which we were able to recover approximately 10% of the BPT that was added. 
Varying the ionic strength of the digestion solutions used, and/or the temperature 
and length of the digestion, did not improve the detection of BPT in human hair. 
Furthermore, poor chromatography, as defined by lack of Gaussian peak shape, 
was observed for most of the samples.  In summary, we were unable to develop 
a GC/MS method for BPT in human hair with a sensitivity below 100 pg/mg BPT 
in fortified human hair. 
 
Analytical method for BPT:  Hemoglobin 
 
 Figure 4.4 shows representative chromatograms for an extracted 1.75 
pg/mg calibration standard and an extracted blank human Hb sample.  The 
assay was determined to be linear from 1.75 to 10 pg/mg. The LLOQ and ULOQ 
were 1.75 and 10 pg/mg, respectively. The coefficient of variations (CV) for intra- 
and interassay imprecision were less than 10% (Table 4.3). 
The stock and intermediate solutions for accuracy and imprecision for 
intra- and interassay samples were made by the quality control officer or other 
Center for Human Toxicology personnel (since only one commercial supplier 
exists for BPT). The stock and intermediate solutions used to make the 
calibration standards were prepared by Sarah Campbell.  
 Accuracy was calculated by first dividing the observed concentration by 
the target concentration then multiplying by 100 to obtain a percentage. The  
percent CV calculated from the mean observed concentrations of samples tested 




















Figure 4.4 Representative ion chromatograms from (A) extracted analyte-free 
(blank) human Hb sample and (B) an extracted BPT-fortified (1.75 pg/mg, LLOQ) 
human Hb sample. Samples shown were also fortified with the internal standard 
(13C6)-BPT. Analyte retention time (RT) is on the x-axis and signal intensity on 
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Accuracy and Imprecision of BPT-fortified Human Hb 
 





Concentration % of Target %CVb 
  pg/mg   pg/mg     
Intraassay 
     
 
3.75 5 3.56 94.8 6.3 
 
6.25 5 5.93 94.8 8.2 
 
8.75 5 9.05 103.5 5.5 
Interassay 
     
 
3.75 15 3.70 98.6 6.5 
 
6.25 15 6.19 99.1 5.9 
 
8.75 15 9.22 105.4 7.8 
            
      





Concentration % of Target %CVb 
  pg/mg   pg/mg     
LLOQ 
     
 
1.75 4* 1.60 91.3 17.2 
      ULOQ 
     
 




    
 
a Number of quality control replicate samples used 
b CV= coefficient of variation 








deviation of the samples tested by the mean observed concentration of the 
samples.  This value was then multiplied by 100 to obtain a percentage.  
The intraassay accuracy and imprecision were determined by analyzing 
five replicate samples of analyte-free human Hb fortified with known amounts of 
BPT at 3.75, 6.25, and 8.75 pg/mg, and analyzed within a single batch.  The 
intra- assay accuracy ranged from 94.8-103.5% of the theoretical target 
concentrations.  The intraassay imprecision ranged from 5.5- 8.2%. 
Interassay accuracy and imprecision were determined by comparing  
calculated concentrations from replicates (n=5 for each concentration, total n=15) 
of analyte-free human Hb samples fortified with BPT at 3.75, 6.25, 8.75 pg/mg 
and analyzed in three separate analytical batches on 3 separate days. The 
interassay accuracy ranged from 98.6 -105.4% of the theoretical target  
concentrations. The interassay imprecision ranged from 5.9-7.8%.  
The LLOQ was evaluated by the analysis of five replicates of BPT-fortified 
to analyte-free human Hb at 1.75 pg/mg. The average accuracy for these 
samples was 91.3%, and the imprecision was 17.2%. 
 The ULOQ was evaluated by the analysis of five replicates of BPT-fortified 
to analyte-free human Hb at 10 pg/mg. The average accuracy for these samples 
was 100.5%, and the imprecision was 8.4%. 
 
Results for clinical trial participants 
 The analytical results for heavy smoking and nonsmoking participants are 
presented in Table 4.4 along with the demographics for each participant.  









     





































101 M 38 Brown Seneca 28 Negative QNS ND 29.3 351.2 
102 F 25 Black Newport Menthol 25 Negative QNS 9.1 20.7 488.0 
103 F 42 Brown Niagara Light 100's 30 Negative QNS ND NA NA 
104 F 32 Black Marlboro menthol 26 Negative QNS ND 7.1 148.3 
105 F 30 Light Brown Exact Lights 25 Positive QNS ND 13.9 137.1 
106 M 33 Brown Newport 20 Negative QNS ND ND 303.3 
107 F 19 Auburn Marlboro 22 Negative QNS ND 23.7 327.4 
109 F 29 Brown Seneca 23 Negative QNS ND 24.2 413.2 
111 F 38 Dark Brown Marlboro Lights 25 Negative QNS ND 12.8 243.0 
112 M 40 Black Marlboro 20 Negative QNS ND 11.4 202.7 
114 F 37 Brown Newport 30 Positive QNS ND 18.2 371.4 
115 M 45 Black Exact lights 25 Negative QNS ND 14.8 247.6 
116 F 28 Brown Newport 30 Positive QNS ND 23.6 353.8 
117 M 42 Dark Brown Newport 25 Negative QNS ND 13.4 148.5 
118 M 30 Brown Marlboro 20 Negative QNS ND 11.9 246.4 
120 M 21 Light Brown Marlboro Reds 25 Negative QNS ND 11.6 164.9 
122 M 27 Dark Brown Marlboro 30 Positive QNS ND NA NA 
123 M 39 Dark Brown Newport 100’s 20 Negative QNS 9.7 12.8 94.9 
124 M 23 Brown Signal 20 Negative QNS ND 14.5 294.8 
       
 
   
CPD – cigarettes per day; ND – not detected; QNS – quantity not sufficient; NA – not available 
a
 – LOD 20 pg/mg; 
b
 – LOD not established; 
c
 – LLOQ 1.75 pg/mg; 
d
 – LLOQ 1 ng/mL; 
e












     





































125 M 28 Black any brand 40 Negative QNS ND 14.5 247.3 
126 M 43 Black any brand 40 Negative QNS ND NA NA 
127 M 28 Dark Brown Seneca 30 Negative QNS ND 42.7 340.5 
128 F 34 Dark Brown Newport 20 Negative QNS ND 22.4 221.7 
129 M 18 Dark Brown Marlboro 20 Negative QNS ND 16.8 148.2 
130 F 21 Dark Brown Marlboro Lights 22 Negative QNS ND 12.8 175.0 
131 F 30 Black Seneca menthol lights 25 Negative QNS ND 19.8 176.7 
132 F 36 Brown Newport 100s 20 Negative QNS ND NA NA 
134 F 28 Black Newport 30 Negative QNS ND NA NA 
135 M 24 Dark Brown Newport 20 Negative QNS ND NA NA 
136 F 22 Light Brown Camel 20 Negative QNS ND 20.9 267.5 
004 F 30 Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
006 F 32 Light Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
007 M 30 Brown Nonsmoker - Positive QNS ND <LLOQ <LLOQ 
008 F 37 Blonde Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
010 M 35 Light Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
011 F 45 Brown Nonsmoker - Positive QNS ND <LLOQ <LLOQ 
012 F 33 Dark Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
013 F 25 Light Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
014 F 27 Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
015 F 23 Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
 
CPD – cigarettes per day; ND – not detected; QNS – quantity not sufficient; NA – not available 
a
 – LOD 20 pg/mg; 
b
 – LOD not established; 
c
 – LLOQ 1.75 pg/mg; 
d
 – LLOQ 1 ng/mL; 
e













     





































016 F 21 Dark Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
017 F 21 Dark Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
018 M 34 Black Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
019 M 21 Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
020 F 34 Black Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
021 M 33 Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
022 M 20 Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
027 F 24 Black Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
028 M 26 Black Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
029 F 32 Dark Brown Nonsmoker - Negative QNS ND <LLOQ <LLOQ 
 
CPD – cigarettes per day; ND – not detected; QNS – quantity not sufficient; NA – not available 
a
 – LOD 20 pg/mg; 
b
 – LOD not established; 
c
 – LLOQ 1.75 pg/mg; 
d
 – LLOQ 1 ng/mL; 
e











verified by the presence of measurable plasma concentrations of nicotine and 
cotinine. (A plasma sample was not available for five of the heavy smoking 
participants.)  Nicotine concentrations ranged from non- detected to 42.7 ng/mL, 
and cotinine concentrations ranged from 94.9 to 488.0 ng/mL for these 
participants. The presence of cotinine concentrations at these levels verified the 
self-reported current smoking status of the participants (typical cotinine 
concentrations for smokers range from 100 ng/mL to >300 ng/mL [200, 201]).  
The self-reported nonsmoking status of the nonsmoking participants was also 
verified by nicotine and cotinine plasma concentrations.  Plasma concentrations 
for both nicotine and cotinine were below their respective LLOQs for all 
nonsmoking participants, confirming their nonsmoking status at the time of 
sample collection. 
Second, hair samples from study participants were analyzed to determine 
whether B(a)P was present in the hair of known smokers and absent in the hair 
of nonsmokers.  Clinical hair samples were considered positive for B(a)P if the 
calculated concentrations were greater than 20 pg/mg, the secondary qualifying 
ion was present, and the chromatograms showed Gaussian peak shape with S/N 
ratio > 3.  Clinical hair samples were considered negative for B(a)P if the 
calculated concentrations were below 20 pg/mg and S/N ratio was <3. Applying 
these criteria, B(a)P was only detectable in four (three females, one male) of the 
30 heavy smoker hair samples, despite the verified current smoking status via 
plasma cotinine concentrations of the participant. Additionally, no abnormal non-





these participants.  For the nonsmoking participants, B(a)P was detectable in two 
(both males) of the 20 participants, despite nonsmoking status via plasma 
cotinine concentrations. No abnormal B(a)P exposed was noted on the screening 
questionnaire for these nonsmoking participants as well.   
 Third, we originally proposed to determine the differences in BPDE-protein 
adducts in the hair of smokers and nonsmokers, however, the quantity of hair 
received from each participant for analysis was between 34 and 200 mg 
(average weight collected was 95 mg). Therefore, given the sample amounts 
required for analysis after initial development and evaluation of analytical 
methods, we determined that the available quantity was not sufficient enough to 
perform both B(a)P and BPDE-protein adduct analyses for the study samples.  
The data for rat hair in Chapter 2, demonstrated that concentrations B(a)P 
concentrations in rat hair are much higher than concentrations of BPT. We also 
demonstrated that concentrations of BPT released from rat hair are about 50% 
lower in hair than released from Hb.  With these factors in mind, we thus 
predicted that there was a greater likelihood to detect B(a)P in human hair, rather 
than BPT in human hair.  Therefore, analysis for B(a)P, rather than BPDE-protein 
adducts, was performed due to the limited quantity of hair available for testing.  
 Despite the insufficient weight for the individual clinical hair samples, 
however, we were able to pool five heavy smoker participant’s hair samples to 
obtain a sufficient quantity of hair to attempt BPDE-protein adduct testing using 
the preparation and extraction detailed in Materials and Methods section of this 





smoker’s hair (data not shown), double the amount of hair was taken through the 
extraction procedure (200 mg vs. 100 mg) (Figure 4.5, panel A).  Despite 
doubling the amount of hair used in the analysis, BPT was still not detected.  
Panel B of Figure 4.5 shows a representative chromatogram from an extracted 
pooled heavy smoker’s hair sample using triple the amount of hair (300 mg).  The 
chromatograms from this sample further illustrate that even when tripling the 
amount of hair for analysis, BPT was still not detected, and this amount of hair  
greatly reduces the quality of the chromatography. Therefore, increasing the 
amount of hair analyzed did not improve the ability to detect BPT in human hair. 
 Fourth, with respect to the detection of BPDE-Hb adducts, only one heavy  
smoker (female) Hb sample had a concentration above the LLOQ.  The  
measured concentration for BPDE-Hb adducts for this individual was 9.1 pg/mg. 
This concentration is several fold higher than the average reported concentration 
for BPDE-Hb adducts in smokers [60, 93, 127].  This individual also had the 
highest plasma concentration of cotinine of the 30 heavy smoking participants.  




 In the present study, we proposed to develop analytical methods for the 
purpose of determining the differences of B(a)P and BPDE-protein adduct 
incorporation in smokers (those exposed to PTS) and nonsmokers (those with no 
exposure to PTS or ETS) hair.  While no previous studies have examined BPDE-















Figure 4.5 Ion chromatograms from: A) an extracted 200 mg pooled heavy, and 
B) an extracted 300 mg pooled heavy smoker’s hair sample.  These 
chromatograms illustrate the reduced sensitivity in the detection of BPT and that 
increasing the amount of hair reduces the quality of the chromatography.  
Analyte retention time (RT) is on the x-axis and signal intensity on the y-axis. 
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panel of PAHs in human hair.  In 2003, Toriba et al. reported an average 
concentration of B(a)P in smokers hair of 1.1 + 0.7 pg/mg and 0.7 + 0.3 pg/mg 
for nonsmokers’ hair  [59].  Given these available data, we originally planned to 
validate a quantitative method for detection of B(a)P in human hair with a 
sensitivity at or below 1 pg/mg.  However, we were unable to achieve adequate 
reproducibility (CV<20%) at concentrations below 20 pg/mg and a qualitative 
evaluation (positive vs. negative at or above 20 pg/mg) was instead performed 
for each hair sample in our study. 
 Using the qualitative method developed for the detection of B(a)P in 
human hair, we detected B(a)P in four of the 30 heavy smoker hair samples, and 
two of the 20 nonsmokers hair samples. There are several possible explanations 
for these findings.  First, concentrations of B(a)P in human hair may be extremely 
low in the group of participants tested, and may be below the LOD of the assay 
and instrument.  Greater sensitivity in the analytical methodology may therefore 
be necessary in order to determine quantitative concentrations of B(a)P in human 
clinical hair samples.  Second, it is also possible that B(a)P is simply not present 
in many human hair samples. Third, as mentioned above, B(a)P concentrations 
in hair have only been reported in one small human study involving 20 
participants (6 smokers, 14 nonsmokers) using HPLC with fluorescence 
detection [59] more than 8 years ago.  Although using this HPLC-fluorescence 
method may have provided greater sensitivity for the detection of B(a)P, it has 
much lower specificity than GC/MS with selective ion monitoring.  In this small 





of 1.1 + 0.7 pg/mg, but evaluation of their blank hair samples (n=4), used for the 
standard curve and quality control samples, revealed virtually the same 
concentrations of B(a)P (1.1 + 0.1 pg/mg) as detected in their smokers’ hair 
samples.  Also of note, no additional studies reporting B(a)P in hair have been 
published to date since this paper. This demonstrates that more research is need 
to evaluate concentrations of B(a)P in human hair, as well as and the factors that 
contribute to its incorporation and retention in hair.  Fourth, the extremely low 
concentrations of B(a)P in human hair may be due in part by daily hygiene 
practices.  We demonstrated that a 10% shampoo wash of B(a)P incorporated 
rat hair greatly reduces the detectable amount of B(a)P several fold (Chapter 2, 
Figure 2.13). Thus the incorporation of B(a)P in hair may not be strong enough to 
resist the typical hygiene practices of humans.  While we do note there are 
significant structural differences in hair of different species, these effects have yet 
to be determined experimentally with human hair.  Finally, B(a)P is 
photochemically reactive and it is unknown whether light penetrating the hair 
shaft reduces the detectable amounts of B(a)P in hair.  
 In addition to the determination of B(a)P content in human hair, numerous 
digestion and extraction experiments were performed on human hair that had 
been fortified with BPT (Table 4.2). These experiments were unsuccessful for the 
detection of BPT in digested and extracted human hair.  There are several 
possible explanations for these findings: 1) Significant ion suppression is present; 
2) There are matrix interferences that were not removed during the extraction of 





in human hair using GC/MS. Given these findings, and the fact that there was an  
insufficient quantity of human clinical hair samples available for analysis, the 
development of a validated method for BPDE-protein adducts in human hair was 
not performed.  We were, however, able to evaluate pooled heavy smokers’ hair 
samples, to determine whether we could detect BPT using the method detailed in 
this chapter, and which we validated in Chapter 2 for rat hair. Despite using two 
and three times the amount of pooled heavy smokers’ hair for this method, we 
were unable to detect BPT (Figure 4.5). 
 BPDE-Hb adducts (from isolated Hb in blood) were selected as our 
positive control in our both our human studies and animal studies, since they 
have been well characterized [60, 98] and are known to form after B(a)P 
exposure, however, we were only able to detect BPDE-Hb adducts from one 
human participant (in contrast to our rat studies in which we were able to detect 
BPDE-Hb adducts from all B(a)P dosed rats, see Chapter 2). However, we do 
note that the doses of B(a)P administered to the rats over seven days was 1000 
fold higher than what the approximated human exposure would be in three 
months (based on the EPA’s estimate of 1-3 ug/day for nonsmokers) [202].  
Alternatively, the lack of detectable BPT released from Hb, may be due to the 
increased instrument noise present in human Hb samples that have only had a 
liquid-liquid extracted performed  on them (vs. the rat samples which went 
through both liquid-liquid and SPE), or that extremely low concentrations of these 
adducts are present in the current set of participants.  It is known that up to 40% 





our results were not entirely unexpected.  We were unable to determine if the 
concentration of these biomarkers correlate to the concentration of the positive 
control (the BPDE-Hb adduct), since virtually all of the samples did not have 
detectable concentrations of analyte. 
 The matrix effects/ion suppression observed with in human hair and Hb 
extracts were much more pronounced than what was seen in rat hair and rat Hb 
(Chapter 2), and may be due in part to the 10-fold increase in the amount of hair 
used in the B(a)P assay, and the 2-fold  increase in the amount of Hb used in the 
BPDE-Hb adduct assay. The BPDE-Hb extraction presented in this chapter was 
also reduced to just a liquid-liquid extraction in order to prevent further loss of 
BPT through SPE.  However, these sample extracts of were very crude (as 
apparent by the large background signal in the chromatograms, Figure 4.4), and 
greatly decreased the instrument’s signal for BPT over time.  Further clean-up of 
samples by SPE or other techniques will be needed in future studies.  In addition 
to analytical modifications for these extraction methods, different instrumentation 
may be necessary for determining extremely low concentrations of BPDE 
adducts in hair and Hb from humans, as discussed below.  
 GC tandem mass spectrometry (GC-MS/MS) may be able to provide 
greater sensitivity and improved ability to detect extremely low levels of B(a)P in 
human hair and BPT released from BPDE-protein adducts.  Recently, Simpson 
et al. published a method for the detection of BPT in the urine of smokers using 
GC/MS-MS) [203].  This instrumentation allowed for detection limits for BPT (“on 





limits for BPT have also been reported with stable isotope dilution high resolution 
GC [93], liquid chromatography-tandem mass spectrometry (LC-MS/MS) [94], as 
well as HPLC with laser-induced fluorescence detection [189].  Lower detection 
limits for B(a)P have also been reported with HPLC using fluorescence detection 
[204] and HPLC with ultraviolet detection [205], however these studies 
determined  B(a)P concentrations in matrices other than hair.   
 Some modifications that may prove advantageous for the detection of 
B(a)P and/or BPDE-protein adducts in hair are:  1) The use of more hair  (>100 
mg) in the assay if coupled to more stringent sample clean-up methods; 2) 
Collection of hair that has been plucked instead of cutting close to the scalp, to 
provide a hair sample that has not been exposed to typical hygiene practices 
and/or light; 3)  Adding a wash procedure before digestion and extraction of 
human hair to possibly reduce matrix interferences/ion suppression.  It is noted 
however, that washing hair as part of the analytical preparation is contentious 
and no general consensus has been reached on the topic. 4)  The analysis of 
more abundant PAHs, and their diol expoxide protein adduct forming 
metabolites, as surrogate analytes for the less abundant B(a)P.   Schummer et 
al. have recently demonstrated that mono-hydroxylated PAH metabolites such 
and hydroxy-napthalene and hydroxyl-phenanthrene can be detected in human 
hair by GC/MS [206]. 
In conclusion, B(a)P, but not BPDE-protein adducts can be detected in hair 
from at least some subjects.  Moreover, the data presented in this chapter 





evaluate these novel hair biomarkers in humans, and more research involving 
human clinical samples will be necessary in order to determine if B(a)P and/or 
BPDE-protein adducts in hair can be a useful tool for assessing B(a)P exposure 


















The objective of this research was to investigate whether B(a)P and BPDE-
protein adducts can be detected in hair and whether they can be used as novel 
biomarkers of toxic exposure to B(a)P.  The overarching hypothesis for this 
research was that B(a)P and BPDE-protein adducts in hair can be used as 
biomarkers of toxic exposures to B(a)P.  To address this hypothesis we 
conducted the following experiments: 
1.  Long-Evans rats were exposed to varying doses of B(a)P. Then using liquid-
liquid, solid phase, and enzymatic extraction techniques, coupled to our sensitive 
and specific GC/MS methods, we quantified B(a)P and BPT (released from 
BPDE- adducts) in biological matrices.  
 From these analyses we determined: 
1a.  B(a)P incorporates into rat hair in a dose-dependent manner. 
1b.  B(a)P concentrations in pigmented and nonpigmented rat hair do not               
statically differ. 
1c.  B(a)P concentrations in rat hair correlate with the concentrations of 





1d.  BPT (released from BPDE-protein adducts) can be detected in rat 
hair, and its concentration is dose-dependent. 
1e.  BPT concentrations in hair are approximately 1.6 times greater in 
pigmented vs. nonpigmented hair. 
2.  A histological approach using a hematoxylin and eosin (H&E) staining was 
used to detect histopathological events the lung tissue from rats with varying 
B(a)P exposure.  This was completed in order to infer whether B(a)P and BPDE-
protein adducts concentrations in hair were associated with the severity 
ofhistopathologic evidence of lung toxicty.  We used subjective and objective 
measures in an attempt to score the severity of the histopathological events for 
B(a)P dosed rats.  We also employed immunohistochemistry staining directed 
towards identification of neutrophils.    
 From these experiments we determined: 
2a.  Rats exposed to B(a)P in the low, medium, and high dosed groups 
show alveolar wall thickening, decreased air space, macrophage 
hyperplasia, and an increased myloperoxidase enzymes. 
2b.  Subjective measurements of the percentage of alveolar wall 
thickening of the lung tissue and neutrophil counts did not statistically 
differ from control rats. 
2c.  Objective measurement of nuclear space, cellular space, air space 






3.  Using samples collected from human clinical trials we sought to investigate 
the differences of B(a)P and BPDE-protein adducts in the hair of active smokers 
(those exposed to PTS) and nonsmokers (those with no exposure to PTS or  
ETS). 
 From these experiments we determined: 
3a.  B(a)P, but not BPDE-protein adducts can be detected in hair from at   
least some human clinical hair samples.   
3b.  More sensitive analytical methodology is be needed to evaluate 
concentrations of these novel hair biomarkers in humans, and further 
research involving human clinical samples will be necessary in order to 
determine if B(a)P and/or BPDE-protein adducts in hair can be a useful 
tool for assessing B(a)P exposure in humans, particularly smokers. 
 
Significance 
In conclusion, we have developed sensitive and specific quantitative 
analytical GC/MS methodology to investigate the disposition and concentrations 
of unique biomarkers in hair from experimental animals exposed to B(a)P and in 
human subjects enrolled in a smoking clinical trial.  To our knowledge, this is the 
first report of B(a)P and BPDE-protein adducts detection in rat hair, and is only 
the second report on the detection of B(a)P in human hair. We determined there 
is a dose-dependent increase of these novel hair biomarkers in rats exposed to 
B(a)P, as well as insights into the role pigment may be playing on their 





underlying mechanisms involving the incorporation of these compounds, the 
results from this dissertational research show promise for biomonitoring of B(a)P  











SCREENING QUESTIONNAIRE FOR NONSMOKERS 
 
  
 Date: _________________  
 Study ID: _________________  
 Recorder’s Name: ________________________________  
 
1. How old are you? (Criterion: 18 or older) 
 
2. Have you ever smoked a cigarette or used tobacco in any form?  
 
 2 a. When did you smoke your last cigarette or use tobacco? 
- Within the past 12 months 
- More than a year ago (Criterion: More than a year ago) 
 
3. How often are you exposed to other people smoking in the same room as 
you? 
- Never 
- Once or twice in a month 
- Once or twice in a week 
- Almost every day (Criterion: Once or twice the last 3 months or less) 
 
4. Do you keep your hair cut an inch and a half or longer? (Criterion: Yes) 
 
5. Have you colored your hair with the past 3 months? (Criterion: No) 
 
6. What color is your hair? (Criterion:  Dark pigmented preferred, no gray or 
white) 
 
7. “Since some chemicals found in tobacco smoke can also be present in certain 
occupational settings, we would like to know – What is your occupation? 
 
8. “Since similar chemicals can also be found in food that has been barbecued 
or smoked we would like to know – How many times per week do you 
consume barbecued or smoked food products? 
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